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SUMMARY Mycobacteria are the causative organisms for diseases such as tubercu-
losis (TB), leprosy, Buruli ulcer, and pulmonary nontuberculous mycobacterial dis-
ease, to name the most important ones. In 2015, globally, almost 10 million people
developed TB, and almost half a million patients suffered from its multidrug-resistant
form. In 2016, a total of 9,287 new TB cases were reported in the United States. In
2015, there were 174,608 new case of leprosy worldwide. India, Brazil, and Indonesia
reported the most leprosy cases. In 2015, the World Health Organization reported
2,037 new cases of Buruli ulcer, with most cases being reported in Africa. Pulmonary
nontuberculous mycobacterial disease is an emerging public health challenge. The
U.S. National Institutes of Health reported an increase from 20 to 47 cases/100,000
persons (or 8.2% per year) of pulmonary nontuberculous mycobacterial disease
among adults aged 65 years or older throughout the United States, with 181,037 na-
tional annual cases estimated in 2014. This review describes contemporary methods
for the laboratory diagnosis of mycobacterial diseases. Furthermore, the review con-
siders the ever-changing health care delivery system and stresses the laboratory’s
need to adjust and embrace molecular technologies to provide shorter turnaround
times and a higher quality of care for the patients who we serve.
KEYWORDS BCG, mycobacterium, Mycobacterium bovis, Mycobacterium tuberculosis,
NTM, diagnostic algorithm, mycobacterial diseases, nontuberculous mycobacteria,
review, tuberculosis
INTRODUCTION
Belonging to the only genus in the family Mycobacteriaceae are a diverse group ofbacteria that differ widely in several traits, such as their pathogenic potential in
humans and animals, reservoirs, and growth dynamics in culture. For the most part, 
mycobacteria can be divided into four major groups based on fundamental differences 
in epidemiology, association with disease, and the ability to grow in vitro: those that 
belong to the Mycobacterium tuberculosis complex, Mycobacterium leprae, and Myco-
bacterium ulcerans and those referred to as nontuberculous mycobacteria (NTM). This 
introductory section provides an overview of their taxonomy and representative spe-
cies belonging to these four major groups involved in human infections.
Taxonomy of Mycobacteria
Mycobacterium spp. contain mycolic acids in their cell wall and share this charac-
teristic with bacteria of other genera such as Gordonia, Nocardia, Rhodococcus, and 
Tsukamurella. This characteristic enables these bacteria to be differentiated from other 
bacteria based on staining techniques since the high mycolic acid content in the cell 
wall makes organisms resistant to decolorization with acid alcohol (i.e., “acid fast”). 
Mycobacterium spp. are aerobic, non-spore-forming, Gram-positive, acid-fast bacilli 
(AFB). They are nonmotile, and most of them are straight or slightly curved rods, with 
only a small number of species exhibiting some branching. Some species are pig-
mented yellow or orange when cultured, and this pigment may be constitutive (i.e., 
scotochromogenic) or induced only with exposure to light (i.e., photochromogenic), 
while other species never produce pigment (i.e., nonphotochromogenic). Compared to 
most other bacteria, mycobacteria are slowly growing, requiring at least 5 days of
incubation, with many requiring 1 or more weeks for visible growth; of note, some do 
not grow at all on solid media (1).
The Mycobacterium genus includes strict pathogens, potential or opportunistic 
pathogens, and nonpathogenic, saprophytic species. Gene sequence similarities within 
the genus (94.3% for the 16S rRNA gene) and robust phylogenetic reconstructions 
using concatenated sequences of housekeeping genes have confirmed the natural 
division between slowly and rapidly growing mycobacteria and have also demon-
strated that all slowly growing mycobacteria belong to a single evolutionary branch 
that emerged from the rapidly growing mycobacteria. This feature is intrinsically linked 
to their pathogenic ability to infect humans, and therefore, all strict pathogens and 
most opportunistic pathogens belong to the evolutionary branch of slowly growing 
mycobacteria (2–4). From 41 valid species in 1980, the genus Mycobacterium currently 
encompasses almost 200 recognized species and subspecies (2–6), many of which 
either can cause clinical disease, have been associated with disease, or have been 
isolated from clinical specimens without any known clinical correlation.
Mycobacterium tuberculosis Complex
Tuberculosis (TB) is caused by a group of closely related, slowly growing mycobac-
teria collectively named the Mycobacterium tuberculosis complex, which infect a large 
spectrum of mammals, including humans. Infection occurs when a person (or animal) 
inhales 1- to 5-m droplet nuclei containing tubercle bacilli that reach the alveoli of the 
lungs. Following exposure, either the M. tuberculosis complex can be killed by the host’s 
immune system; active TB disease can occur in different areas of the body such as 
regional lymph nodes, lung, kidneys, brain, larynx, and bone; or latent TB infection 
(LTBI) may be established. Latency refers to the condition of chronic infection without 
clinical signs or symptoms of pulmonary TB (7). LTBI is significant because these 
patients serve as a major reservoir of the M. tuberculosis complex in the population and 
because these patients can develop active pulmonary TB if they become immunosup-
pressed.
The M. tuberculosis complex is comprised of M. tuberculosis, Mycobacterium bovis, 
Mycobacterium bovis bacille Calmette-Guérin (BCG), Mycobacterium caprae, Mycobacte-
rium africanum, Mycobacterium pinnipedii, Mycobacterium microti, Mycobacterium orygis, 
Mycobacterium mungi (8), dassie bacillus (9), chimpanzee bacillus (10), and the rare, 
smooth-colony-morphology tubercle bacillus named Mycobacterium canettii (11). The 
M. tuberculosis complex shares identical matrix-assisted laser desorption ionization–
time of flight mass spectrometry (MALDI-TOF MS) profiles, high-performance liquid 
chromatography (HPLC) patterns, and 16S rRNA gene sequences, with 99% identity 
at the nucleotide level for some species. However, despite these similarities, complex 
members differ significantly in morphology, biochemistry, host spectra, disease pat-
terns in animals, antimicrobial susceptibility testing (AST) data, geographic ranges, and 
epidemiological patterns. The use of nucleic acid amplification tests (NAATs), including 
Amplified MTD (MTD; Hologic Inc., San Diego, CA) and Xpert MTB/RIF (Xpert; Cepheid, 
Sunnyvale, CA), cannot usually differentiate among members of this complex, although 
specific primers can be used to differentiate complex members with some sequencing 
methods. At present, there is only one commercial test, the Genotype MTBC line probe 
assay (Hain Lifescience, Nehren, Germany), that has the ability to differentiate among 
some of the members of the M. tuberculosis complex, such as M. tuberculosis, M. bovis, 
M. bovis BCG, M. africanum, M. microti, and M. caprae, from growth-positive cultures 
(broth or solid medium) or directly from AFB smear-positive, processed specimens (12).
Mycobacterium tuberculosis. M. tuberculosis has killed more than 100 million people 
over the last 100 years (see references 13 and 14 for more detailed information 
regarding the pathophysiology, clinical manifestations, diagnosis, and treatment of TB). 
The global burden of TB is enormous. In 2015, an estimated 10.4 million people 
developed TB, and 1.8 million died, including HIV-infected individuals (15). In 2015, 
there were an estimated 1.2 million new TB cases in HIV-positive individuals (11% of all 
new cases of TB), 60% of whom were living in India, Indonesia, China, Nigeria, Pakistan,
and South Africa. Although the mortality rate from TB has fallen 22% between 2000 and 
2015, TB is one of the top 10 causes of death worldwide.
In 2016, a total of 9,287 new TB cases were reported in the United States. This 
represents the lowest number of TB cases on record and a 2.7% decrease from the 
number in 2015. The 2016 TB incidence of 2.9 cases per 100,000 persons represents a 
slight decrease compared with the incidence in 2015. However, epidemiological mod-
eling demonstrates that if similar, low rates of decline continue, the goal of U.S. TB 
elimination (1 case/million population) will not be reached during this century (16).
Drug resistance among M. tuberculosis isolates can develop in two ways, with 
primary resistance occurring in persons who are initially exposed to and infected with 
resistant organisms. In contrast, secondary resistance, or acquired resistance, develops 
during TB therapy, either because the patient was treated with an inadequate regimen, 
because the patient did not take the prescribed regimen appropriately, or because of 
other conditions such as drug malabsorption, an inadequate potency of the compound, 
or drug-drug interactions that led to low serum levels. By the end of 2015, data on TB 
drug resistance were available for 155 countries, accounting for more than 95% of the 
world’s population and estimated TB cases. Globally, an estimated 3.9% of new cases 
and 21% of previously treated cases have multidrug-resistant TB (MDR-TB), i.e., resis-
tance to at least rifampin (RIF) and isoniazid (INH), and RIF-resistant TB; these levels 
have remained virtually unchanged in recent years. In 2015, there were an estimated 
480,000 new cases of MDR-TB worldwide, with 100,000 RIF-resistant TB cases. India, 
China, and the Russian Federation accounted for 45% of the 580,000 combined cases. 
Extensively drug-resistant TB (XDR-TB) was reported by 117 countries by 2015. An 
estimated 9.5% of people with MDR-TB have XDR-TB. XDR-TB is defined as resistance to 
INH and RIF plus resistance to any fluoroquinolone (FQ) and at least one of three 
injectable second-line anti-TB drugs (i.e., kanamycin, capreomycin, or amikacin) (15).
Mycobacterium bovis. M. bovis causes TB in warm-blooded animals, including cattle, 
deer, and elk, and can be transmitted to primates and humans. Up to 30% of TB cases 
in Europe were caused by M. bovis in the 1900s and were transmitted to humans largely 
via the inhalation of infectious droplets from infected cattle and the consumption of 
contaminated, unpasteurized dairy products (17). The introduction of milk pasteuriza-
tion and cattle control programs in 1917 all but eradicated M. bovis from cattle and 
humans in most of the United States and other resource-rich nations. Fewer than 0.02%
of U.S. cattle tested positive by a tuberculin skin test (TST) in 2002, and 0.002% of 
377,000 cattle tested in a 2008 California M. bovis investigation were positive (18). A 
study of human TB cases in the United States from 1995 through 2005 estimated that 
only 1.4% of cases were still caused by M. bovis, most of which were among individuals 
born outside the United States, resulting in about 230 cases per year (19). However, 
more recently, in certain regions of the United States, such as along the border of 
Mexico, and in Mexican-born individuals in New York City (17), the prevalence M. bovis 
has been shown to be significantly higher than the national prevalence. In San Diego, 
CA, over 45% of all culture-confirmed TB cases in children and 8% of all TB cases in 2004 
to 2007 were due to M. bovis, primarily due to the consumption of unpasteurized 
cheese products (20).
Isolates of M. bovis are intrinsically resistant to pyrazinamide (PZA) but may be 
susceptible to other drugs used for the treatment of TB. This is one reason why it is 
important to identify M. tuberculosis complex isolates to the species level. People at risk 
for acquiring M. bovis include individuals who work with cattle, bison, deer, or elk or 
products from these animals, such as hides, milk, or meat. People who drink raw 
(unpasteurized) milk or consume dairy products made from raw milk are also at a 
higher risk. People who might be at a higher risk for M. bovis infection should talk to 
their health care providers about whether they should be regularly screened for TB 
infection using either the TST or an interferon gamma (IFN-) release assay (IGRA) (21).
Mycobacterium bovis BCG. The live, attenuated BCG strain of M. bovis is used for TB 
vaccination; of note, this strain is not pathogenic in most hosts. Vaccination is used in 
high-prevalence areas primarily to prevent disseminated disease in young children;
vaccination protocols for these young children result in a 60 to 80% decrease in the 
incidence of TB (22). BCG vaccination is not used in low-prevalence countries such as 
the United States and other industrialized countries. Instillation of BCG into the bladder 
can also be used to treat bladder cancer given its ability to act as a strong tumor-
immunomodulatory therapy. However, some individuals treated for bladder cancer can 
develop infections with M. bovis BCG in different organs; of importance is the differ-
entiation of M. bovis from M. bovis BCG (23). Disseminated BCG infection as a result of 
TB vaccination is a rare complication, with an incidence of 0.06 to 1.56 cases per million 
vaccinations, occurring exclusively in patients with immune deficits. However, in these 
cases, the prognosis is unfavorable; up to 70% of patients die, despite intensive 
antituberculosis treatment (24). The rapid differentiation of M. bovis and M. bovis BCG 
diseases from M. tuberculosis disease is crucial for optimizing treatment, contact 
investigation, and implementing additional control measures at various levels of the 
health care system.
Latent tuberculosis infection. About one-third of the world’s population has LTBI. 
In the United States, the National Health and Nutrition Evaluation Survey (1999 to 2000) 
estimated the prevalence of LTBI among civilian, noninstitutionalized, and nonhome-
less populations to be about 11.2 million (4.2%) individuals (25). In a more recent survey 
(2011 to 2012), the prevalence of LTBI was estimated to be 12.4 million (4.4%) 
individuals (26). People infected with M. tuberculosis have a lifetime risk of developing 
active TB of 10% (27). However, persons with compromised immune systems, such as 
people living with HIV, malnutrition, or diabetes, have a much higher risk of progression 
from LTBI to active disease. For example, individuals living with HIV and infected with 
M. tuberculosis have a 7 to 10% annual risk of developing active TB disease (28).
Mycobacterium leprae and Mycobacterium ulcerans
M. leprae and M. ulcerans are also notable mycobacterial pathogens. Since leprosy 
and Buruli ulcer are very distinct diseases, they are not included as NTM.
Mycobacterium leprae. M. leprae, a very slowly growing Mycobacterium species, is 
the cause of leprosy, a chronic granulomatous disease that affects the skin, peripheral 
nervous system, and mucous membranes. Patients with leprosy are classified as having 
paucibacillary or multibacillary disease. Paucibacillary (low numbers of organisms) 
disease is the milder form and is characterized by one or more skin macules. Multiba-
cillary (large numbers of organisms) leprosy is associated with symmetric skin lesions, 
nodules, plaques, thickened dermis, and frequent involvement of the nasal mucosa. 
Lesions may be AFB smear microscopy positive.
M. leprae cannot be grown by using routine bacteriologic media, commercial 
automated detection systems, or cell culture. However, the bacteria can be grown for 
research purposes in mouse footpads and, more recently, in nine-banded armadillos, 
which are also susceptible to leprosy. For the most part, leprosy is diagnosed based on 
clinical signs and symptoms (29), with most diagnoses being made clinically in com-
bination with suggestive pathological findings of skin lesions, although molecular 
techniques may also play a diagnostic role (30, 31).
In 2015, the number of new cases worldwide was 174,608 (corresponding to a 
prevalence rate of 0.29 cases per 10,000 population, a decrease in the rate of detection 
of new cases from 0.32 per 10,000 population in 2014) (29). India reported the highest 
number of new cases (127,326, or 60% of new cases), followed by Brazil (26,395) and 
Indonesia (17,202). In 2015, 178 new cases occurred in the United States; 72% of these 
new cases were reported by California, Florida, Hawaii, Louisiana, New York, and Texas 
(30). Worldwide, 1 million to 2 million individuals are disabled because of leprosy, but 
with appropriate treatment, these individuals are considered free of active infection.
Person-to-person spread via inhalation of infectious droplets is the usual mode of 
transmission of M. leprae. In the past, patients in the United States with leprosy were 
taken care of in sanatoria; the last sanatorium for the management of leprosy closed in 
1999, with federally supported outpatient clinics being available throughout the United 
States and Puerto Rico for treatment. Diagnostic assistance is available from the National
Hansen’s Disease Programs in Baton Rouge, LA (30, 32). Multidrug therapy must be 
used as therapy for leprosy to prevent or slow the development of resistance. For 
example, RIF is combined with dapsone to treat paucibacillary leprosy, while RIF and 
clofazimine are now combined with dapsone to treat multibacillary leprosy (33).
Mycobacterium ulcerans. M. ulcerans is a strict pathogen of humans. Disease ranges 
from a localized nodule or ulcer to widespread ulcerative or nonulcerative disease, 
including osteomyelitis. If untreated, severe limb deformities with contractures and 
scarring are common (1). In Africa, the disease is referred to as Buruli ulcer, while in 
Australia, it is called Bairnsdale ulcer. Nevertheless, disease mediated by M. ulcerans is 
the third most common mycobacterial disease in the world (34).
Evidence suggests that M. ulcerans may be transmitted through mild injury to the 
skin after exposure to contaminated environmental sources such as water or soil (35).
Although M. ulcerans has never been cultured directly from environmental waters 
that are associated with human infections and the mode of transmission is unknown 
(36), aquatic insects isolated from the wild in areas where Buruli ulcer is endemic can 
be naturally colonized with M. ulcerans, and aquatic insects infected in the laboratory 
are able to infect mice by biting (37). In humans, the unique pathogenic capacity of M. 
ulcerans is due to the secretion of a potent macrolide toxin, mycolactone, encoded by 
a plasmid that causes tissue damage and inhibits the immune response (38).
M. ulcerans needs a temperature of between 29°C and 33°C and a low (2.5%) 
oxygen concentration to grow. Since growth detection is difficult and has a low 
yield, molecular techniques are preferable for diagnosis (39–41). During a World 
Health Organization (WHO) meeting on Buruli ulcer in 2013 (42), a new recommen-
dation for laboratory diagnosis was proposed: national control programs should 
strengthen laboratory confirmation of cases to ensure that at least 70% of all 
reported cases are laboratory confirmed by positive PCR.
It is difficult to determine the true incidence of disease caused by M. ulcerans 
since it is not easily isolated in laboratories. In 2015, according to the WHO, 2,037 
new cases of M. ulcerans infection were reported globally in 13 countries, with the 
majority of cases being reported from West and Central Africa (34). Because M. 
ulcerans is most often associated with tropical wetlands, it is thought to proliferate 
in mud beneath stagnant waters (43). Individuals of all ages and both sexes may be 
infected; many are children under 15 years of age. Finally, overwhelming evidence 
indicates that 8 weeks of RIF-streptomycin or 4 weeks of RIF-streptomycin followed 
by 4 weeks of RIF-clarithromycin or 8 weeks of other oral regimens achieve 
recurrence-free healing of Buruli ulcer (44).
Nontuberculous Mycobacteria
Nontuberculous Mycobacterium spp. have been called a variety of names, from 
atypical mycobacteria to MOTT (mycobacteria other than TB), and today are most 
frequently called nontuberculous mycobacteria or NTM. For many years, the Runyon 
classification (45) of Mycobacterium was utilized in clinical laboratories to provide a 
convenient way to differentiate among NTM based on the rate of growth of the 
organism from subculture and pigment production. With the increasing use of molec-
ular and other nontraditional biochemical means of identification, this classification 
system is no longer universally used and has limitations; however, most mycobacteri-
ologists would agree that the differentiation of the NTM into those that are slowly 
growing NTM (requiring 7 days to produce mature colonies on solid media from a 
dilute inoculum under ideal conditions) and those that are rapidly growing NTM 
(producing mature colonies on solid media in 7 days when subcultured on appro-
priate media) remains useful. Table 1 lists more recently identified novel species of 
NTM. Many of the listed species have been isolated from rare cases of human disease, 
but with newer molecular methods, more of these mycobacteria may be recognized in 
clinical specimens and correlated with disease. Table 1 also provides information about 
growth rates (rapid or slow growth). Furthermore, species that are closely related to the
TABLE 1 List of novel NTM species described since 2011a
Novel species or subspecies (reference)c Yr of description Type of growth Close relative(s)
M. abscessus subsp. abscessus (78) 2011 Rapid M. abscessus
M. abscessus subsp. bolletii (78) 2016 Rapid M. abscessus
M. abscessus subsp. massiliense (78) 2016 Rapid M. abscessus
M. algericum (305) 2011 Rapid M. terrae complex
M. alsense (306) 2016 Slow M. asiaticum
M. anyangense (307) 2015 Rapid M. smegmatis-M. fortuitum
M. arabiense (308) 2013 Rapid M. neoaurum-M. hodleri
M. arcueilense (309) 2016 Rapid M. fortuitum group, M. septicum, M. farcinogenesb
M. bourgelatii (310) 2013 Rapid M. intermedium
M. celeriflavum (311) 2015 Rapid M. moriokaense
M. engbaekii (312) 2013 Rapid M. hiberniae
M. europaeum (313) 2011 Slow M. simiae
M. fragae (314) 2013 Slow M. celatum
M. franklinii (315) 2015 Rapid M. chelonae-M. abscessus
M. helvum (316) 2016 Rapid No relation to any characterized type strains of mycobacteria
M. heraklionense (312) 2013 Slow M. arupense
M. hippocampi (317) 2014 Rapid M. flavescens-M. goodii
“M. icosiumassiliensis” (318) 2016 Slow M. terrae complex
M. iranicum (319) 2013 Rapid M. gilvum
M. koreense (320) 2012 Slow M. triviale
M. litorale (321) 2012 Rapid M. monacense
M. longobardum (312) 2013 Slow M. terrae
M. lutetiense (309) 2016 Rapid M. fortuitum group, M. septicum, M. farcinogenesb
“M. malmesburyense” (322) 2016 Rapid M. moriokaense
“M. massilipolynesiensis” (323) 2017 Rapid M. phlei
M. minnesotense (324) 2013 Slow M. arupense
M. montmartrense (309) 2016 Rapid M. fortuitum group, M. septicum, M. farcinogenesb
M. oryzae (325) 2016 Rapid M. tokaiense, M. murale
M. paraense (326) 2015 Slow M. interjectum
M. paragordonae (327) 2014 Slow M. gordonae
M. paraintracellulare (70) 2016 Slow M. intracellulare
M. parakoreense (328) 2013 Slow M. koreense
M. saopaulense (329) 2015 Rapid M. chelonae, M. abscessus
M. sarraceniae (316) 2016 Rapid No obvious relation to any characterized type strains of
mycobacteria
M. sediminis (308) 2013 Rapid M. neoaurum, M. hodleri
M. sherrisii (330) 2011 Slow M. simiae
M. shinjukuense (331) 2011 Slow M. tuberculosis complex, M. marinum, M. ulcerans
“M. virginiense” (332) 2016 Slow M. terrae complex
M. yongonense (71) 2013 Slow M. intracellulare
aSee reference 6.
bM. farcinogenes is also a slowly growing mycobacterium, although some rapidly growing mycobacteria are genetically related to this species. 
cSpecies in quotation marks are proposed names and do not yet have a standing in nomenclature.
novel species are also listed, which may be helpful for the identification of an isolate
under study.
The plethora of newly described species seen in the last few decades is in part the
consequence of the availability and increased reliability of new DNA sequencing
methods that can differentiate even closely related species and in part the conse-
quence of an increased frequency of isolation of mycobacteria (46–50). The latter may
be the result of newly emerging, human-made reservoirs (e.g., treated urban water and
sewage systems, swimming pools, hot tubs, pedicure footbaths, showers, and medical
devices) for certain species. Other species, like Mycobacteria gordonae, are common in
both natural and artificial sources. NTM can form biofilms on a wide range of organic
(plastic, silicone, rubber, and PVC) and inorganic (glass, metals, and metallic fluids of
machines) materials due to their hydrophobic cell wall and their resistance to disin-
fectants, antibiotics, or heavy metals. In both natural and human-made environments,
biofilms may have an important role in protecting NTM against aggressive external
factors and promoting their colonization. This colonization by NTM in biofilms may lead
to contamination that can be a source of either pseudoinfections or true NTM diseases.
Pseudoinfections may be the result of contamination during the collection of speci-
TABLE 2 Clinical and microbiological criteria for diagnosis of nontuberculous mycobacterial lung diseasea
Criterion type Description
Clinical (i) Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a high-resolution computed tomography
scan that shows multifocal bronchiectasis with multiple small nodules and (ii) appropriate exclusion of other
diagnoses
Microbiological (i) Positive culture results from at least 2 separate expectorated sputum samples, and if the results from 2 sputum
samples are nondiagnostic (i.e., culture negative), consider repeat sputum AFB smears and cultures; (ii) positive
culture result from at least 1 bronchial wash or lavage specimen; or (iii) transbronchial or other lung biopsy
specimen with mycobacterial histopathological features (granulomatous inflammation or AFB) and positive culture
for NTM or biopsy specimen showing mycobacterial histopathological features (granulomatous inflammation or AFB)
and 1 or more sputum or bronchial wash specimens that are culture positive for NTM
Patient management (i) Expert consultation should be obtained when NTM that either are infrequently encountered or usually represent
environmental contamination are recovered; (ii) patients who are suspected of having NTM lung disease but do not
meet the diagnostic criteria should be monitored until the diagnosis is firmly established or excluded; and (iii)
making the diagnosis of NTM lung disease does not, per se, necessitate the institution of therapy, which is a decision
based on potential risks and benefits of therapy for individual patients
aAdapted from reference 52 with permission of the American Thoracic Society (copyright © 2007 American Thoracic Society).
mens (e.g., biofilms in improperly cleaned endoscopes) (51) or contamination during 
laboratory testing (e.g., a contaminated water source for reagent preparation). Pseu-
doinfections may be recognized by an increase in the number of AFB smear-positive 
specimens, an increase in the frequency of detection of a particular NTM species, or an 
increase in the prevalence of a peculiar AST pattern. While pseudoinfections do not 
necessarily cause disease, they can create difficult diagnostic dilemmas (52, 53).
According to the American Thoracic Society (ATS)/Infectious Diseases Society of 
America (IDSA) 2007 statement (52), when NTM are suspected as the etiology of 
disease, definitive diagnosis should always be supported by repeated isolation of NTM 
from several specimens of the patient or a single specimen if it is collected aseptically 
from a sterile body site. However, laboratory identification of potentially pathogenic or 
saprophytic NTM alone is not enough to direct patient care. Laboratory results should 
always be correlated with the individual’s clinical presentation and radiological and 
histological findings (Table 2) to determine the clinical significance, if any.
For the purposes of this article, this group of organisms is divided into two major 
groups, i.e., slowly growing NTM and rapidly growing NTM.
Slowly growing nontuberculous mycobacteria frequently involved in human 
disease. NTM may result in colonization, infection, and/or disease (52, 54). Colonization 
and infection can be transient, intermittent, or prolonged. Since humans are in regular 
contact with NTM in the environment, NTM can be detected in the respiratory and 
gastrointestinal tracts or on the skin of healthy individuals.
NTM may grow in natural and human-made environments, such as treated urban 
water and sewage systems; swimming pools; hot tubs; pedicure footbaths; showers; 
tattoo inks; fish tanks; or medical devices such as endoscopes and their washing 
machines and heater-cooler devices, ice machines used to refrigerate surgical solutions, 
and inadequately sterilized surgical equipment or solutions (52, 54). Certain NTM such 
as Mycobacterium avium or Mycobacterium marinum are more commonly recoverable 
from artificial sources, while the natural reservoir of Mycobacterium kansasii and Myco-
bacterium xenopi is currently unknown.
Most NTM are ubiquitous environmental microorganisms that can be recovered 
from soil and both treated and untreated freshwater and seawater (2, 3, 5, 52, 55). Since 
NTM may be found in both natural and human-made reservoirs, human infections are 
suspected to be acquired from these environmental sources. However, the identifica-
tion of the specific source of infection is usually not possible. NTM diseases are not 
reportable diseases in many public health jurisdictions since they are not considered 
communicable; therefore, surveillance data are limited and unreliable (52, 54).
Marras et al. (47) reported an increase in the rate of detection of pulmonary NTM 
isolates in Ontario, Canada, from 9.1 cases per 100,000 persons in 1997 to 14.1 cases per 
100,000 persons in 2003. In a follow-up study (48), that same research group measured
Molecular identification studies have revealed numerous additional sequence
the prevalence and temporal trends of pulmonary NTM disease among residents of 
Ontario, Canada, from 1998 to 2010. The 5-year prevalence increased from 29.3 cases 
per 100,000 persons from 1998 to 2002 to 41.3 cases per 100,000 persons in 2006 to 
2010.
Adjemian et al. (50) described the prevalence and trends of pulmonary NTM disease 
among adults aged 65 years or older throughout the United States. From 1997 to 2007, 
the annual incidence significantly increased from 20 to 47 cases/100,000 persons, or 
8.2% per year. Women were 1.4 times more likely to be diagnosed with pulmonary NTM 
than men. Relative to whites, Asians/Pacific Islanders were twice as likely to be infected, 
whereas blacks were half as likely.
(i) Mycobacterium avium complex. Pulmonary infection caused by the Mycobacte-
rium avium complex (MAC) can occur in immunocompetent hosts; disseminated infec-
tions usually occur in people living with HIV. The most common presentations of MAC 
lung infections in immunocompetent hosts are TB-like apical fibrocavitary disease or 
interstitial nodular infiltrates and bronchiectasis. MAC can also be associated with 
hypersensitivity pneumonitis, which is also known as “hot tub lung.” This syndrome is 
a combination of inflammatory reactions and infectious mechanisms and is the result 
of exposure to contaminated indoor spas or showers. In children, cervical lymphadenitis 
is the most common presentation (56).
The MAC is frequently isolated in laboratories in the United States. Diseases caused 
by the MAC are not consistently reportable throughout the United States (57). Dissem-
inated MAC infection has been associated with people living with HIV with low CD4 
counts, but since the introduction of highly active antiretroviral therapy, the incidence 
in this population is declining. The MAC is acquired from the environment and is not 
thought to be spread from person to person. Recently, Mycobacterium chimaera, a  
species within the MAC, was implicated in causing disease from the use of contami-
nated heater-cooler devices used in open heart surgery (58–60).
Strollo et al. (61) reported that state-specific numbers of cases and costs are critical 
for quantifying the burden of pulmonary NTM disease in the United States. Available 
direct-cost estimates of NTM disease-related medical encounters were applied to NTM 
disease prevalence estimates derived from Medicare beneficiary data (2003 to 2007), 
and persons younger than 65 years of age were included, with case estimates based on 
the age distribution of cases from a reported survey of NTM treatment (62). In 2010, 
those authors estimated that there were 86,244 national cases, totaling to $815 million 
in costs for disease management. Costs of medical encounters among individuals aged 
65 years and older ($562 million) were 2-fold higher than those for individuals younger 
than 65 years of age ($253 million). Projected 2014 estimates resulted in 181,037 
national annual cases ($1.7 billion in costs).
The members of the MAC are slowly growing mycobacteria with smooth, flat, and 
transparent colonies. The MAC is one of the NTM that is most commonly identified as 
a pathogen in respiratory specimens. Historically, the MAC included two species, M. 
avium and Mycobacterium intracellulare. For the M. avium species, four subspecies have 
been assigned, M. avium subsp. avium, M. avium subsp. hominissuis, M. avium subsp. 
paratuberculosis, and M. avium subsp. silvaticum (63).
M. avium subsp. avium is associated with avian TB, while M. avium subsp. hominissuis 
is the etiological agent of disseminated disease in humans (especially in AIDS patients 
with low CD4 counts), chronic lung diseases in patients with cystic fibrosis (CF) or 
bronchiectasis, or cervical lymphadenitis in children (63–66). Infections with M. avium 
subsp. paratuberculosis result in a chronic granulomatous enteric infection in cattle 
(Johne’s disease) and may have a similar role in Crohn’s diseases in humans (67, 68). M. 
avium subsp. silvaticum has been isolated from wood pigeons, a crane, a penguin, roe 
deer, and a hazel hen; however, due to the lack of a reliable method to identify this 
organism until recently, there has been a lack of data regarding its pathogenicity and 
zoonotic potential (69). M. intracellulare is primarily a respiratory pathogen in humans, 
and an association with disseminated diseases is less common (63).
variants within the MAC, of which Mycobacterium colombiense, M. chimaera, Myco-
bacterium vulneris, Mycobacterium marseillense, Mycobacterium timonense, Mycobac-
terium arosiense, Mycobacterium yongonense, Mycobacterium paraintracellulare, and 
Mycobacterium bouchedurhonense were recently elevated to the species level (52, 
54, 70–72). The standard treatment of MAC disease includes macrolides (clarithro-
mycin or azithromycin), ethambutol (EMB), and a rifamycin (RIF or rifabutin). If a 
more aggressive therapy is required, an injectable aminoglycoside (streptomycin or 
amikacin) may be added to this combination (52, 54).
(ii) Mycobacterium kansasii. M. kansasii is a slowly growing photochromogenic 
mycobacterium. M. kansasii is the second most common cause of NTM disease in some 
regions of the United States, England, Wales, and France (64). The isolation of the 
bacteria in human specimens is almost always associated with disease. The major 
reservoir of the bacteria is likely to be tap water. The primary manifestation of M. 
kansasii infection resembles that of pulmonary TB, with cavitary infiltrates in the upper 
lobes. However, noncavitary and nodular-bronchiectatic lung disease has also been 
observed. Risk factors include pneumoconiosis (especially in miners), chronic obstruc-
tive lung disease, malignancy, and alcoholism. Disseminated infections can be observed 
in patients with impaired cellular immunity. The recommended therapy for M. kansasii 
infections is INH, RIF, and EMB. M. kansasii also shows low MIC values for clarithromycin, 
amikacin, and FQ (52, 54).
(iii) Mycobacterium xenopi. Clinical and radiological disease manifestations of M. 
xenopi infection vary according to the patient’s immunological status and can be 
classified into three groups: a cavitary form in patients with preexisting pulmonary 
disease, a solitary nodular form in immunocompetent patients, and an acute infiltrate 
form in immunosuppressed patients (73). M. xenopi lung disease usually develops in 
individuals with chronic obstructive pulmonary disease or bronchiectasis with an apical 
cavitary radiological appearance. Extrapulmonary cases with joint and soft tissue 
infections have also been observed.
M. xenopi, a slow-growing thermophilic mycobacterium with an optimal growth 
temperature of 42°C to 45°C, was first isolated from skin lesions of Xenopus laevis, an  
African toad. It can frequently be recovered from hot water systems, especially in 
hospitals, which may also lead to nosocomial (hospital) infections or pseudoinfections 
(contamination of clinical specimens or bronchoscopes during collection). M. xenopi is 
second to the MAC as a cause of NTM lung disease in Canada, the United Kingdom, and 
certain parts of Europe. The optimal treatment regimen for M. xenopi includes clari-
thromycin or azithromycin, EMB, and RIF (52, 54).
(iv) Mycobacterium malmoense. M. malmoense was first isolated from a patient in 
Malmö, Sweden. M. malmoense is usually recovered from sputum or cervical lymph 
nodes of children or adults with underlying chronic pulmonary disease, often with 
cavitary involvement; to date, most of the isolates have been reported from northern 
Europe, Zaire (Democratic Republic of Congo), and Japan. The numbers of infections 
with M. malmoense, however, may be underestimated since growth detection is long, 
requiring up to 8 to 12 weeks of incubation. Of significance, treatment of pulmonary M. 
malmoense infection may be complicated. The recommended therapy includes INH, RIF, 
and EMB with or without macrolides and FQ (52, 54).
(v) Mycobacterium haemophilum. M. haemophilum is a fastidious mycobacterium 
with an optimal growth temperature of 28°C to 30°C that grows better on solid medium 
and requires hemin or hemoglobin as an iron source. Due to these special growth 
conditions, this organism is often underrecognized. The temperature preference is in 
line with the fact that M. haemophilum usually infects cooler body sites such as the 
extremities. Most infections are reported in AIDS patients. Additional cases are associ-
ated with other immunosuppressed patients, especially those with solid-organ trans-
plants, bone marrow recipients, or long-term steroid users. The classical clinical pre-
sentation is multiple skin lesions or ulcerations appearing on the extremities that are 
occasionally associated with abscesses, fistulas, or osteomyelitis. Infections were also 
identified in immunocompetent children with cervical lymphadenitis and in a patient
with a pulmonary nodule. The optimal therapy for M. haemophilum is unknown. 
Regimens may include clarithromycin, rifamycins (RIF and rifabutin), and FQ (52, 54).
(vi) Mycobacterium genavense. M. genavense is a fastidious, slowly growing myco-
bacterium that shows better recovery in liquid medium supplemented with mycobactin 
J, especially at an acidic pH (pH 5.5). It was first isolated from the blood of a patient with 
AIDS in Geneva, Switzerland. Clinical isolation of M. genavense is usually associated with 
HIV-related or other causes of immunosuppression. This mycobacterium was recovered 
from AIDS patients with disseminated diseases; individuals with lymphadenitis; bone 
marrow, liver, spleen, stool, and blood samples; and individuals with genital and soft 
tissue infections. M. genavense is one of the most common mycobacterioses in pet birds 
(74). Susceptibility testing of M. genavense is complicated by the fact that the bacterium 
is difficult to grow and shows preferable growth at an acidic pH. An optimal therapy has 
not been determined, but therapy may include clarithromycin, rifamycins, FQ, and 
aminoglycosides (amikacin) (52, 54).
(vii) Mycobacterium marinum. M. marinum is a photochromogenic, slowly growing 
(8 to 12 days) organism that optimally grows at temperatures of between 30°C and 
33°C. M. marinum is the causative agent of “swimming pool” or “fish tank” granuloma, 
which is the result of finger, hand, arm, elbow, knee, or toe soft tissue injury in 
freshwater or saltwater due to punctures from fins of fish or shrimp or from cleaning of 
fish tanks or swimming pools. However, proper chlorination significantly decreased its 
colonization in swimming pools. The typical presentation is a single papule on an 
extremity that may progress to a shallow ulcer, usually 2 to 3 weeks after inoculation. 
Severe complications may also include osteomyelitis of the bones and tenosynovitis 
and arthritis of the joints. Treatment may include surgical debridement and treatment 
with clarithromycin and EMB or EMB and RIF. In cases of deep-structure involvement, 
a combination of clarithromycin, EMB, and RIF can be considered (52, 54).
(viii) Mycobacterium szulgai. M. szulgai is a slowly growing mycobacterium that is 
scotochromogenic at 37°C and photochromogenic at 25°C (75). Recovery of M. szulgai 
from the environment is rare and very unusual. Therefore, similar to M. kansasii, 
isolation of the bacteria in clinical laboratories almost always has clinical significance. 
The clinical presentation of pulmonary infections with M. szulgai is indistinguishable 
from that of TB and usually develops in middle-aged men with alcohol abuse, smoking, 
and chronic obstructive pulmonary disease. Other extrapulmonary clinical manifesta-
tions may include cervical lymphadenitis, cutaneous infections, osteomyelitis, tenosyn-
ovitis, bursitis, or disseminated infections in both AIDS patients and immunocompetent 
patients. M. szulgai shows low MIC values for most antituberculosis drugs; therefore, a 
three- to four-drug regimen may be recommended (52, 54).
(ix) Mycobacterium scrofulaceum. M. scrofulaceum is a slowly growing mycobacte-
rium that is scotochromogenic at 25°C and 37°C. Its name is derived from the histo-
logical term “scrofula,” used to describe infections of the cervical lymph nodes by 
mycobacteria. Wolinsky documented a change from M. scrofulaceum to MAC as the 
common cause of mycobacterial cervical lymphadenitis in children in the 1980s (76). 
AST data are not available, and standardized treatment regimens for M. scrofulaceum 
have not been determined. Confirmed disease-causing isolates of M. scrofulaceum 
should have AST performed on them (52).
Rapidly growing nontuberculous mycobacteria frequently involved in human 
disease. Many newly recognized species belonging to the genus Mycobacterium are 
rapidly growing mycobacteria such that these organisms constitute approximately half 
of the currently recognized/validated mycobacterial species. Rapidly growing myco-
bacteria not only represent many species but also are responsible for a range of disease 
manifestations in the human host, vary widely in their AST profiles, and reside in a vast 
number of environmental reservoirs.
Rapidly growing NTM are very commonly isolated in clinical laboratories and can be 
the cause of significant local and disseminated diseases. A review of all rapidly growing 
mycobacteria is beyond the scope of this document; only those most commonly 
implicated in human infection are briefly discussed here.
(i) Mycobacterium abscessus and its subspecies. M. abscessus and its subspecies are 
often isolated from clinical specimens from CF patients. These organisms are environ-
mental, being found worldwide in water, soil, and dust, and are responsible for a wide 
variety of infections. These organisms often cause infections of skin and soft tissue, but 
they can cause more serious infections, including disseminated disease. Severe lung 
infections can occur in persons with underlying chronic lung disease, including patients 
with CF. Other individuals with underlying respiratory conditions or impaired immune 
systems can be at risk for lung infections. Skin infections are often caused by injections 
of substances contaminated with M. abscessus, via invasive medical procedures when 
contaminated equipment is utilized, or by pedicures (77).
Until recently, there was no evidence of human-to-human or animal-to-human 
transmission of NTM. However, two recent reports investigating outbreaks in CF 
patients using thorough conventional epidemiological and state-of-the-art molecular 
typing investigations, such as whole-genome sequencing, indicated the potential 
transmission of M. abscessus (M. abscessus subsp. abscessus, M. abscessus subsp. bolletii, 
and M. abscessus subsp. massiliense [78]) among these patients (79, 80). These results 
have challenged the dogma of the lack of person-to-person transmission of NTM.
Two studies from the United Kingdom (80, 81) utilized whole-genome sequencing 
and epidemiological analyses to assess the potential for person-to-person transmission 
of M. abscessus among CF patients. First, a retrospective study by Bryant et al. (80) 
examined the genetic relatedness of 168 M. abscessus isolates from 31 adult CF patients 
obtained during 2007 to 2011. Overall, those researchers concluded that person-to-
person transmission of M. abscessus within the hospital was a plausible explanation for 
their phylogenomic and epidemiological observations. A second, more recent study by 
Harris et al. (81) employed an approach similar to that of Bryant et al. to test for 
potential cross-infection among a cohort of pediatric CF patients. Those researchers 
performed whole-genome sequencing on 27 M. abscessus isolates from 20 pediatric 
patients. Their epidemiological data, however, did not identify opportunities for trans-
mission between patients, except for one sibling pair who lived in the same household. 
That study did not include environmental sampling within the hospital and, therefore, 
could not rule out a common source of infection on-site. Their conclusion was that the 
collective study data did not suggest cross-transmission of M. abscessus between 
pediatric CF patients.
Although the taxonomy of organisms belonging to the Mycobacterium abscessus 
complex has been somewhat controversial, whole-genome sequencing data strongly 
support the presence of three subspecies: M. abscessus subsp. abscessus, M. abscessus 
subsp. bolletii, and M. abscessus subsp. massiliense (78). M. abscessus, a nonchromogenic 
and rapidly growing mycobacterium, can be recovered from environmental sources 
and is the most pathogenic and chemotherapy-resistant rapidly growing mycobacte-
rium. Human diseases include pulmonary infections and skin, soft tissue, and bone 
infections that usually develop following trauma or surgery or postinjection. M. absces-
sus is a frequently isolated respiratory NTM, after the MAC, and accounts for more than 
80% of all rapidly growing mycobacterial respiratory infections. Patients with lung 
disease due to M. abscessus are usually white, female nonsmokers older than 60 years 
of age without predisposing factors. Predisposing conditions that are commonly asso-
ciated with M. abscessus pulmonary infections are bronchiectasis with reticulonodular 
lung infiltration, CF, and, rarely, lipoid pneumonia and gastrointestinal disorders with 
chronic vomiting. Patients with these predisposing factors are usually younger than 
40 years of age. Approximately 80% of M. abscessus subsp. abscessus isolates are 
resistant to clarithromycin by an inducible erm(41) gene (82). Of note, this organism 
can also possess an additional erm-like gene, efflux pumps, an aminoglycoside 
2=-N-acetyltransferase, and 12 other homologs of aminoglycoside phosphotrans-
ferases (83); therefore, treatment of diseases caused by this bacterium is often very 
challenging, and cure is rare unless the disease is limited or there is a focal disease 
presentation. Curative therapy may include surgical resection of focal (lung) in-
volvements and/or combined multidrug therapy with macrolides and amikacin,
M. chelonae, tobramycin is more active than amikacin), clarithromycin, linezolid, imi-
penem, or clofazimine. To date, the Clinical and Laboratory Standards Institute (CLSI)
has not addressed susceptibility testing for clofazimine, and as such, there are no
standardized breakpoints or quality measures available. Usually, clarithromycin can be
combined with a second agent to prevent the development of macrolide resistance.
The removal of foreign bodies is also essential (52, 54).
(iii) Mycobacterium fortuitum complex. M. fortuitum is an environmental, nonchro-
cefoxitin, or imipenem. M. abscessus subsp. abscessus and M. abscessus subsp. bolletii 
(a rare cause of human infection) contain an inducible erythromycin methylase erm 
gene that confers resistance to macrolides; therefore, these drugs should always be 
given in combination therapy (52, 54). The correct identification of the subspecies of M. 
abscessus is important, as M. abscessus subsp. massiliense is known to possess a 
nonfunctional erm gene, and as such, macrolide therapy may be effective (84, 85).
(ii) Mycobacterium chelonae complex. The M. chelonae complex consists of M. 
chelonae and three additional validated species (Mycobacterium franklinii, Mycobacte-
rium immunogenum, and Mycobacterium salmoniphilum) (52). M. chelonae, a key human 
opportunistic pathogen, is a nonchromogenic, rapidly growing mycobacterium that is 
widely recoverable from human-made environments such as tap water or from fresh-
water and seawater. The most common clinical manifestations are skin, soft tissue, and 
bone infections, often related to infected piercing wounds, contaminated tattoo inks, 
plastic surgery, or liposuction. Disseminated diseases have been described in immu-
nocompromised individuals, especially in those receiving high-dose steroids. Infections 
may also be associated with ophthalmic surgery or contact lens wear (keratitis). 
Pulmonary infections by M. chelonae are less common than are those by M. abscessus 
(86). Regimens for the treatment of M. chelonae infections may include tobramycin (for
mogenic, and rapidly growing mycobacterium. The M. fortuitum complex includes the 
species M. fortuitum, Mycobacterium peregrinum, Mycobacterium senegalense, Mycobac-
terium setense, Mycobacterium septicum, Mycobacterium porcinum, Mycobacterium hou-
stonense, Mycobacterium boenickei, Mycobacterium brisbanense, and Mycobacterium 
neworleansense. M. fortuitum is frequently associated with skin, soft tissue, and bone 
infections, while it rarely causes pulmonary disease, except in cases of lipoid pneumo-
nia, gastroesophageal disorders, or disseminated diseases. Skin and soft tissue infec-
tions are common after mammoplasty and similar plastic surgery interventions or 
cardiac surgery (sternal wound infections). Footbaths in pedicure salons have also been 
identified as a source of M. fortuitum-associated furunculosis. M. fortuitum infections 
can usually be treated with a two-drug regimen based on in vitro susceptibility testing. 
This regimen may include FQ, doxycycline, amikacin, or sulfonamides. Although most 
M. fortuitum isolates are resistant to clarithromycin, certain members of the M. fortuitum 
complex, namely, Mycobacterium peregrinum and Mycobacterium senegalense, do not  
contain an inducible erythromycin methylase erm gene that confers resistance to 
macrolides (87). The removal of foreign bodies such as breast implants is also essential 
to clear infections (52, 54).
REGULATORY REQUIREMENTS AND GUIDELINES FOR TESTING MYCOBACTERIA 
Introduction
The following section covers many of the regulatory aspects and best practices to 
address when testing for mycobacteria, especially for the M. tuberculosis complex, in 
the clinical laboratory.
Safety considerations are paramount when working with M. tuberculosis complex 
organisms. Prior to the passage of the Occupational Safety and Health Act (OSHA) in 
1970, the employer had the sole responsibility of providing a safe workplace. Safety 
regulations and laws now come from federal, state, and local governments, and 
accrediting organizations and the Centers for Medicare and Medicaid Services (CMS) 
cover safety. Additional details on biosafety are covered in Biosafety, below.
Clinical Laboratory Improvement Amendments
TABLE 3 CLIA-approved proficiency testing programsb
Test
Proficiency testing performed by programc:
AAB API CAP WSLH MPEP (TB only) Accutest AAFP-PT
CLIA approved for 2017 Yes Yes Yes Yes Yes Yes
Acid-fast stain Yes Yes Yes Yes Yes Yes
Mycobacteriology identification Yes Yes Yes Yes
Mycobacteriology antimicrobial susceptibility testing Yes Yes Yesa Yes
Molecular detection of M. tuberculosis complex and
rifampin resistance
Yesa Yesa Yesa
aUngraded (educational) at this time.
bSee reference 333.
cAAB, American Association of Bioanalysts; API, American Proficiency Institute; CAP, College of American Pathologists; WSLH, Wisconsin State Laboratory of Hygiene;
MPEP, Model Performance Evaluation Program (Centers for Disease Control and Prevention); AAFP-PT, American Academy of Family Physicians proficiency testing
program.
The regulation of U.S. clinical laboratories began after the Medicare and Medicaid 
laws went into effect in 1966. The Clinical Laboratory Improvement Amendments (CLIA) 
of 1967 established minimum standards for Medicare-participating laboratories en-
gaged in interstate commerce (i.e., only a relatively small portion of clinical laborato-
ries). In the 1980s, intensive media coverage of poor cytology laboratory practices, 
especially in the reading of Papanicolaou smears, and charges of lax enforcement of 
federal regulations contributed to the passage of the 1988 CLIA and the regulations 
that now define standards of cytology laboratory practice in the United States (88). The 
1988 CLIA require that all laboratories performing human clinical testing have a 
certificate issued by the CMS, bringing all laboratories performing this testing under 
federal regulations. The 1988 CLIA regulations (final publication in 1992) are based on 
test method complexity: waived complexity, moderate complexity, and high complex-
ity. The requirements become more stringent as the testing becomes more complex. 
The CLIA specify quality standards for proficiency testing, patient test management, 
quality control, personnel qualifications, and quality assurance for laboratories perform-
ing moderate- and/or high-complexity tests. The CLIA cover approximately 251,000 
laboratory entities (89).
Also, two U.S. states, New York (90) and Washington (91), have state licensure 
programs that have exemption from CLIA program requirements (92). These states 
have inspection programs that the CLIA deemed at least as rigorous as a CLIA 
inspection.
All laboratories must be certified to perform testing on human specimens under 
CLIA (89). If the laboratory provides services in the subspecialty of mycobacteriology, 
the laboratory must meet the CLIA requirements specified in Title 42 Code of Federal 
Regulations (CFR) 493.1230 through 493.1256, 493.1262, and 493.1281 through 
493.1299. The 1988 CLIA differentiate five types of laboratories for proficiency testing 
purposes: (i) those that interpret acid-fast stains and refer specimens to another 
laboratory appropriately certified in the subspecialty of mycobacteriology; (ii) those 
that interpret acid-fast stains, perform primary inoculation, and refer cultures to another 
laboratory appropriately certified in the subspecialty of mycobacteriology for identifi-
cation; (iii) those that interpret acid-fast stains and isolate and perform identification 
and/or AST of M. tuberculosis but refer other mycobacterial species to another labora-
tory appropriately certified in the subspecialty of mycobacteriology for identification 
and/or AST; (iv) those that interpret acid-fast stains and isolate and identify all myco-
bacteria to the extent required for correct clinical diagnosis but refer AST to another 
laboratory appropriately certified in the subspecialty of mycobacteriology; and (v) those 
that interpret acid-fast stains, isolate and identify all mycobacteria to the extent 
required for correct clinical diagnosis, and perform AST on the organisms isolated. For 
institutions in the United States that offer proficiency testing programs for mycobac-
teriology, see Table 3.
As of 1 January 2016, an “individualized quality control plan” (IQCP) is an alternate 
quality control option to Title 42 CFR 493.1250. Instead of the CLIA quality control 
regulatory requirements, an IQCP may be implemented to meet CLIA quality control 
compliance, permitting the laboratory to customize its quality control plan according to 
the test method and use, environment, and personnel competency while providing 
equivalent quality testing; however, the laboratory cannot do less quality control than 
the manufacturer requires (93).
College of American Pathologists Requirements
The College of American Pathologists (CAP) has requirements pertaining to labora-
tory testing for mycobacteria (94). These include collection, transport and handling, 
reporting of results, medium/stain/reagent quality control (QC), controls and standards, 
AFB smear staining, the use of rapid methods for identification, inoculation on appro-
priate media, and safety considerations. The following turnaround times for specific 
tests are recommended: within 24 h of receipt for AFB smears and within 28 days for 
conventional AST results for the M. tuberculosis complex.
International Organization for Standardization 15189 Standard
International standards for clinical laboratories include the International Organiza-
tion for Standardization (ISO) 15189 standard (95), which specifies the quality manage-
ment system requirements particular to medical laboratories. It was developed by the 
ISO and last updated in 2012. While the ISO 15189 standard is based on the ISO/
International Electrotechnical Commission 17025 standard (96) and the ISO 9001 
standard (97), it is a unique document that takes into consideration the specific 
requirements of the medical environment and the importance of the medical labora-
tory to patient care. In the United States, both the CAP and the American Association 
for Laboratory Accreditation accredit to this international standard.
Statements Related to Mycobacterial Diseases from Various Professional Societies 
and Agencies
Official American Thoracic Society/Infectious Diseases Society of America/Centers 
for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tubercu-
losis in Adults and Children. In the 2017 official statement of the ATS, the IDSA, and the 
Centers for Disease Control and Prevention (CDC), endorsed by the European Respira-
tory Society in 2016 (98), diagnostic testing for TB was described. There are 23 
evidence-based recommendations about diagnostic testing for LTBI, pulmonary TB, and 
extrapulmonary TB.
An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontu-
berculous Mycobacterial Diseases. An Official ATS/IDSA Statement: Diagnosis, Treatment, 
and Prevention of Nontuberculous Mycobacterial Diseases (52) (under revision) provides, 
among other topics, clinical and microbiological criteria for diagnosing pulmonary NTM 
(Table 2). Key laboratory features of NTM health care and hygiene-associated disease 
prevention, prophylaxis, and treatment of NTM disease are described.
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society Consensus 
Recommendations for the Management of Non-Tuberculous Mycobacteria in Individ-
uals with Cystic Fibrosis. The U.S. Cystic Fibrosis Foundation and the European Cystic 
Fibrosis Society convened a panel of 19 experts to develop consensus recommenda-
tions for the screening, investigation, diagnosis, and management of NTM pulmonary 
disease in individuals with CF. A series of pragmatic, evidence-based recommendations 
as an initial step in optimizing management for this challenging condition was gener-
ated (99).
World Health Organization. The WHO produces numerous guidelines and policies 
regarding TB, Buruli ulcer, and leprosy diagnosis, along with biosafety recommenda-
tions; these can be accessed at www.who.org.
Healthy People 2020. Healthy People 2020, published in 2010 by the U.S. Department 
of Health and Human Services (DHHS), provides science-based, 10-year national objec-
tives for improving the health of all Americans. Achieving these objectives is dependent
TABLE 4 Tests and turnaround times to be tracked by the laboratorya
Result Recommended turnaround time
AFB smear (negative and positive) Report AFB smear results within 24 h of specimen receipt
Positive TB NAAT Report within 48 h of specimen receipt
New M. tuberculosis complex-positive culture results from
any specimen source
Report culture identification of M. tuberculosis complex within
21 days of specimen receipt
M. tuberculosis complex first-line AST results on isolates that
demonstrate resistance to any of the first-line drugs
Report first-line AST result within 28 days of specimen collection
aSee references 242 and 334.
in part on the ability of health agencies at all levels of the government and on 
nongovernmental organizations to assess objective progress. For 3 decades, Healthy 
People has established benchmarks and monitored progress over time to encourage 
collaborations across communities and sectors, empower individuals toward making 
informed health decisions, and measure the impact of prevention activities. Healthy 
People is the basis for state and territorial health planning in many jurisdictions.
There is only one objective pertaining to the TB laboratory in Healthy People 2020 (100): 
to increase the proportion of culture-confirmed TB patients with a positive nucleic acid 
amplification test (NAAT) result reported within 2 days of specimen collection (Immuniza-
tion and Infectious Diseases 32). In 2008, the baseline year, 32% of culture-confirmed TB 
patients with a positive NAAT result had their test results reported within 2 days of 
specimen collection; the new goal is to achieve 77% by the year 2020. In 2015, the 
percentage for this objective was 46% (101).
Centers for Disease Control and Prevention
Metrics. To reduce transmission and to prevent further acquired TB, the CDC 
recommends that laboratories monitor the turnaround time by tracking the date/time 
of collection of specimens to the date/time of receipt by the laboratory. In addition, the 
length of time for generating and reporting results concerning AFB smear, NAAT, 
growth detection, identification, and AST results should be monitored (see Table 4 for 
tests and turnaround times) (102, 103): within the health care system, rapid transpor-
tation of specimens or positive AFB cultures to the laboratory either via courier or 
overnight with next-day delivery is encouraged.
Import permit. The CDC’s Import Permit Program regulates the importation of 
infectious biological agents, infectious substances, and vectors of human disease into 
the United States, including M. tuberculosis. Prior to the issue of an import permit, the 
CDC reviews all applications to ensure that entities have appropriate safety measures 
in place for working safely with these important materials. Upon review of the appli-
cation for an import permit, the CDC will contact the facility if an on-site inspection is 
required to evaluate whether the importer’s biosafety measures are commensurate 
with the hazard posed by the infectious biological agent, infectious substance, and/or 
vector and the level of risk given its intended use (104).
International Air Transport Association and U.S. Department of Transportation 
Packaging and Shipping Requirements
Federal and international regulations must be met when using the U.S. Postal 
Service (USPS) or a commercial courier service to send specimens containing etiological 
agents, including M. tuberculosis. Proper packaging reduces the number of broken 
specimens, contains and absorbs leaking specimens, and helps ensure the safety of 
personnel handling them (103). Additional information about shipping of specimens/
isolates of mycobacteria include Title 49 CFR Transportation Parts 100 and 185, avail-
able electronically and from the U.S. Government Printing Office (http://www.access 
.gpo.gov/); International Air Transport Association (IATA) dangerous-goods regulations 
(http://www.iata.org/); USPS regulations on hazardous materials, Domestic Mail Manual 
C023 (http://pe.usps.gov/); and information from the U.S. Department of Transportation 
(DOT) (http://www.dot.gov/), the Transportation Safety Institute (http://www.tsi.dot 
.gov/), and the International Civil Aviation Organization (http://www.icao.int/).
State Requirements
California and New York, among other states, have additional specific requirements 
for AFB testing and reporting of mycobacteriology results. The following states have 
their own licenses/permits for the performance of medical laboratory testing for 
specimens originating from a health care facility from that state: California, Florida, 
Maryland, New York, Pennsylvania, and Rhode Island. Laboratories should determine if 
they must comply with these states’ regulations for performing tests on residents from 
these states and adhere to reporting requirements for M. tuberculosis complex, and in 
some states, reporting requirements for NTM.
IDEAL ALGORITHM/ALTERNATIVE ALGORITHMS FOR TESTING SPECIMENS FOR 
MYCOBACTERIAL DISEASES
The algorithms for testing specimens for mycobacteria are complicated since several 
tests and several appropriate algorithms may be used in the clinical laboratory. 
Ultimately, any methods and algorithms used should ensure that the M. tuberculosis 
complex is detected or ruled out as quickly as possible and that NTM are detected and 
identified to help to determine if they are clinically significant. This section provides a 
testing algorithm for specimens for TB and discusses some of the alternative options, 
including the decision to refer services to another laboratory.
Figure 1 shows an ideal diagnostic algorithm as proposed by the writing committee 
of this document for specimens from patients with suspected TB and specimens from 
patients with a low suspicion for TB but who need mycobacterial infection ruled out. 
Determining the best algorithm is dependent on the facility, its staffing and testing 
capabilities, and the patient population served. Some issues to consider when choosing 
an algorithm are the number of specimens that are tested, the prevalence of TB and 
other mycobacterial diseases in the patient population served (for example, a low-
prevalence setting), the skills of the laboratory staff, the availability of appropriate 
facilities for handling and manipulating mycobacterial organisms, and the availability of 
reference or public health laboratory services (105).
Tests for Detecting or Ruling Out Mycobacterium tuberculosis Complex Infection
Any algorithm for testing specimens from patients with suspected TB should include 
a NAAT for the M. tuberculosis complex. The NAAT should ideally be performed on all 
first-time TB-suspect patients, and results should be reported within 48 h of specimen 
receipt (106). A NAAT should be performed directly on the specimen, and there are 
several methods available, including the commercial MTD and Xpert assays as well as 
laboratory-developed tests. NAATs are discussed in more detail in Nucleic Acid Ampli-
fication Tests, below.
NAATs may need to be modified and validated for off-label use for other specimen 
types with the caveat that test performance may be different. It is important to 
determine the best NAAT for the patient population served by the laboratory and 
whether NAATs will be performed on respiratory specimens only or whether nonrespi-
ratory specimens will also be validated and tested. An additional consideration is 
whether a NAAT will be performed on at least one specimen from all individuals who 
are first-time TB-suspect patients or whether testing will include only AFB smear-
positive specimens. For example, if the NAAT is performed on AFB smear-positive 
specimens only, then it will be performed on a concentrated, processed specimen after 
an AFB smear result is available. In the ideal algorithm, a NAAT is performed irrespective 
of the AFB smear result, and therefore, the specimen can be tested as soon as it is 
received, with results reported earlier. If NAAT for detection of TB is not offered by the 
laboratory, this test should be sent to a reference laboratory or to a state or local public 
health laboratory.
NAAT-positive specimens can be tested for resistance to at least RIF by a molecular 
method. A M. tuberculosis complex isolate that is resistant to RIF is often resistant to 
INH, and therefore, a molecular method that screens for resistance to at least RIF can 
be considered a proxy test for MDR-TB. In some cases, this screen may be performed
FIG 1 Schematic of the ideal algorithm for mycobacteriology testing in clinical and public health laboratories MTBC,
Mycobacterium tuberculosis complex; NAAT, nucleic acid amplification test; AFB, acid-fast bacilli; MDR, multidrug resistant; PHL,
public health laboratory.
only on patients with certain risk factors for MDR-TB, e.g., those who are foreign born, 
who have had contact with an MDR-TB case, who were previously treated for TB, or who 
were treated and were nonadherent. However, in the ideal algorithm, this screen is 
performed on all NAAT-positive specimens. Options for tests include the Xpert assay, 
which is an FDA-market-authorized test for the detection of the M. tuberculosis complex 
and mutations associated with RIF resistance. There are also several other laboratory-
developed tests, such as Sanger sequencing and pyrosequencing, and research-use-
only tests such as line probe assays, e.g., Hain Genotype MTBDRplus and MTBDRsl. With 
any laboratory-developed test, thorough validation must be performed prior to imple-
mentation to determine test performance and applicability (107–110). If the MDR 
screen, i.e., testing for molecular drug resistance, either RIF and INH or RIF only, is not
offered by the laboratory, the specimen should be sent to a reference laboratory or to 
a state or local public health laboratory. If the local or state public health laboratory 
does not have the capability to perform the MDR screen, specimens can be referred to 
the CDC, if certain criteria are met. The molecular detection of antimicrobial resistance 
using NAATs is discussed further in “Detection of Antimicrobial Resistance,” below.
If the MDR-TB screen results are positive and RIF resistance (or RIF and INH 
resistance) is detected, further testing must be performed for confirmation and the 
detection of additional drug resistance. Additional testing allows the confirmation of 
RIF monoresistance versus MDR-TB and ruling out pre-XDR-TB or XDR-TB (111). These 
MDR-TB screen-positive specimens can be sent to a reference laboratory, to a state or 
local public health laboratory, or to the CDC through a U.S. public health laboratory.
Since 2012, the Molecular Detection of Drug Resistance (MDDR) program at the CDC 
has offered pyrosequencing and DNA sequencing of genes associated with resistance 
to RIF and INH to rapidly identify potential MDR-TB cases (see “Molecular AST methods,” 
below). In addition, an extended panel that covers genetic loci associated with resis-
tance to EMB, PZA, FQ, and the injectable agents (amikacin, kanamycin, and capreo-
mycin) can be performed to detect XDR-TB cases. The MDDR program accepts isolates 
and NAAT-positive sputum sediments submitted by a U.S. public health laboratory. 
Submission must be preapproved by the CDC and is dependent on patient risk factors 
for MDR-TB and clinical history, including a known resistance result and drug allergy. 
The MDDR service can also provide molecular testing in situations where there are 
mixed/nonviable cultures and conventional methods are unsuccessful (112). NAATs for 
the detection of antimicrobial resistance are discussed further in “Detection of Antimi-
crobial Resistance,” below.
An AFB smear and a culture should be performed on all specimens submitted for 
mycobacterial testing, except for blood, for which an AFB smear is not applicable. A 
concentration method and a fluorescent-stain technique that enhances the ability to 
identify AFB in a specimen should be used, as detailed in Smear Microscopy and 
Growth Detection of Acid-Fast Bacilli, below. When an AFB smear is performed to 
confirm the presence of AFB in a culture, a Ziehl-Neelsen or Kinyoun stain is adequate. 
It is essential that specimens be inoculated in solid and liquid media to increase the 
recovery of mycobacteria. In most cases, cultures can be finalized as negative at 6 
weeks/42 days when using a commercial broth system. One alternative to this protocol 
would be to incubate cultures for an additional 2 weeks before reporting the culture as 
negative if, for example, the AFB smear is positive or a fastidious organism is suspected, 
e.g., M. genavense or M. haemophilum. If specialized media or growth conditions that 
are not available in the facility are required, the specimen should be sent to a reference 
laboratory. The details of these methods are discussed in Work-Up of Specimens, below. 
Culture is still the gold standard for the laboratory diagnosis of TB disease. Instrument-
flagged broth cultures or growth on solid medium requires confirmation of AFB by 
smear microscopy prior to performing identification. Identification methods may in-
clude molecular methods such as Sanger sequencing, the use of DNA probes, NAATs, 
lateral flow assays, HPLC, or MALDI-TOF MS (details of these identification methods are 
discussed in Identification, below). Whichever methods are chosen, they should be 
performed frequently enough so that the M. tuberculosis complex can be identified or 
ruled out within 24 h of detection of an AFB-positive culture. Also, species identification 
of members of the M. tuberculosis complex (113) may need to be considered since 
treatment for Mycobacterium bovis BCG-Mycobacterium bovis differs from treatment for 
other M. tuberculosis complex species (12, 114). If a NTM is isolated, test methods should 
be available to provide species-level and subspecies-level identification for clinically 
significant isolates. Alternatively, these specimens may also be referred to another 
laboratory for identification, if warranted.
Once a culture has been confirmed to be positive for M. tuberculosis complex, AST 
should be performed by a culture-based method; however, there are a limited number 
of commercially available methods in the United States. The agar proportion (AP) 
method is the gold standard but requires considerable technical expertise. Details on
automated broth susceptibility systems can be found in Antimicrobial Susceptibility 
Testing, below. AST needs to be performed on at least one isolate from a first-time TB 
patient and can be repeated after 60 days if the patient is not improving clinically or 
has not converted to AFB smear-negative status. If a member of the M. tuberculosis 
complex is isolated from a different specimen source, it may also be appropriate to 
perform AST on a single isolate from that source. At least one isolate from each TB case 
should be sent to the jurisdictional public health laboratory for genotyping (details of 
the public health laboratory requirements can be found in Public Health Requirements, 
below).
Tests for Detecting or Ruling Out NTM/Low Suspicion for TB Disease
As with M. tuberculosis complex, any testing algorithm for the detection of NTM 
should always include an AFB smear and culture. See above for discussion regarding 
ideal testing for AFB smear and culture.
The first step in any testing algorithm for NTM should be a rapid method to rule out 
TB. In certain patient populations, such as CF patients or other immunocompromised 
patients, a rapid method to detect NTM may also be valuable. For example, some 
laboratories perform a laboratory-developed multiplex assay for the detection of the M. 
tuberculosis complex and one of the more common NTM, MAC. Otherwise, waiting for 
growth and performing identification of NTM isolates is the standard approach. 
Instrument-flagged broth cultures or growth on solid medium requires confirmation as 
AFB by smear microscopy prior to performing identification. As indicated above, there 
are various methods for the identification of mycobacteria. Methods such as HPLC and 
conventional biochemicals with phenotypic characteristics may be used, but some of 
these more traditional methods are not discriminative enough with the changing 
nomenclature and expanding number of new species within the genus Mycobacterium 
(details of these identification methods are discussed in Identification, below). If a NTM 
is identified, consultation with a physician experienced in NTM diseases may be 
necessary to determine whether the NTM is clinically significant and whether further 
testing, including AST, is warranted. The recovery and identification of NTM in CF and 
other immunocompromised patients are particularly important. For example, consid-
eration of NTM pulmonary disease in CF patients should be based on clinical and 
laboratory findings. If NTM are identified, AST is essential to guide appropriate therapy 
(99). Finally, appropriate methods and technical skills should be available to identify 
mixed infections with M. tuberculosis complex-NTM or mixed species of NTM. If appro-
priate methods and technical skill are not available to work up mixed cultures, the 
culture should be sent to a reference laboratory or public health laboratory.
Algorithm Summary/Frequently Asked Questions
The following six questions were identified and answered by the writing committee 
of this document and are based on available guidelines and expert opinions.
Can NAAT replace AFB smear? Although NAAT is a rapid method for detecting TB, 
there can be false-negative results, depending on the quality of the specimen, the 
specific NAAT used, the bacterial load in the specimen, and sampling bias within 
specimens. In addition, most NAATs do not detect NTM, and a negative NAAT result for 
TB and a positive AFB smear are good indicators of the presence of NTM. In the 
algorithm, the NAAT and AFB smear can be performed concurrently so that the NAAT 
is not dependent on the result of the AFB smear. It is important for the health care 
provider to interpret the NAAT result in conjunction with that of the AFB smear.
Do an AFB smear and culture need to be in the algorithm when a NAAT is 
performed? AFB smear and culture should always be performed. An AFB-positive smear 
result gives the health care provider with valuable information. Culture is more sensi-
tive and is still the gold standard.
When should a reflex MDR-TB screen be performed on a NAAT-positive speci-
men? A reflex MDR-TB screen should ideally be performed on all first NAAT-positive 
specimens or on initial TB isolates if the MDR-TB screen was not performed on the
original specimen or sediment. If this test is not performed, referring the specimen to 
a reference laboratory or a local or state public health laboratory should be considered.
When should identification be performed on a specimen positive for AFB?
Identification should be performed on all AFB-positive specimens, as they may be 
clinically significant. It is important to rule M. tuberculosis complex in or out once a 
culture becomes AFB positive. Ideally, this testing should be performed daily. If a 
laboratory is performing culture, having probes for identification may be useful, as they 
can provide a fast result for the most common species. If identification methods are not 
available, laboratories should refer isolates to an appropriate reference laboratory or 
public health laboratory.
How does the algorithm change for nonrespiratory specimens? At this time, there 
is no FDA-approved or -cleared NAAT for nonrespiratory specimens. It is recommended 
that each laboratory determine the need for testing on these specimen types and the 
performance characteristics associated with such testing.
What should be done when discrepant test results are obtained? The introduction 
of NAATs to the diagnostic options can yield discrepant test results, where one method 
yields a positive test result and another method yields a negative test result. As the 
use of NAATs and other molecular methods increases, discrepancies among these test 
results will occur. Clinical interpretations of discrepant test results can be challenging. 
The explanations for these discrepancies include specimen quality, the fact that mo-
lecular tests may target different sections of the microbial genome, and sampling bias. 
Most importantly, it should be remembered that no single test is 100% accurate, and 
whenever multiple tests for the same analyte are performed, there may be discrepant 
results between tests.
Health care providers interpreting discrepant results may be referred to a TB expert 
for assistance. In the United States, health care providers may contact Tuberculosis 
Centers of Excellence (funded by the CDC), in addition to other TB experts (115).
BIOSAFETY
The most important biosafety issue for diagnostic testing of specimens that could 
contain mycobacteria is that of the M. tuberculosis complex and aerosolization of bacilli 
in droplet nuclei. Protection of workers from laboratory transmission requires the use 
of standard laboratory precautions, good laboratory practices, safety devices, personal 
protective equipment, and appropriate decontamination and disposal of biological 
hazards. The use of sharps should be carefully assessed, i.e., replacement of glass 
pipettes by plastic pipettes when possible and evaluation of how needles and syringes 
are used in the laboratory. Because there is no a priori method of knowing which 
specimens may contain mycobacteria and which do not, all steps in specimen acqui-
sition, processing, and disposal must be designed to protect providers and laboratory 
personnel from exposure to infectious droplet nuclei (116).
Risk Assessment
Because the scope and scale of testing vary widely among laboratories, no single set 
of safety guidelines or recommendations is applicable to all laboratories that perform 
mycobacteriology testing. Every laboratory should perform risk assessment and strat-
ification that can be used to guide the development of a biosafety program for that 
laboratory (117). Approaches to risk assessment and stratification are available from the 
WHO (118), the Association of Public Health Laboratories (103), the U.S. DHHS, and the 
CDC (119). Performing risk assessment and stratification allows laboratory directors to 
design risk mitigation programs appropriate for each laboratory. As detailed in the 
WHO document, laboratories can be divided into low-, moderate-, and high-risk categories 
(118). Low-risk laboratories, which typically manipulate specimens only to perform 
AFB smears with or without the use of a molecular assay, correlate with U.S. DHHS 
recommendations for using biosafety level 2 (BSL-2) conditions and practices. Moderate-
risk laboratories, which process specimens for inoculation onto culture media and may 
perform direct AST (from a processed AFB smear-positive sediment), correlate with U.S.
DHHS recommendations for using BSL-3 conditions and practices (119). High-risk 
laboratories, which process mycobacterial cultures to identify M. tuberculosis and may 
perform indirect AST (from a positive TB culture), also correlate with CDC recommen-
dations for using BSL-3 conditions and practices (119). As the use of molecular 
diagnostic assays increases, particularly self-contained systems with little or no need for 
specimen processing (e.g., Xpert), risk assessment and stratification may be necessary 
in parts of the laboratory that traditionally have not performed mycobacteriology 
testing.
Specimen Processing
All specimen processing must be performed in a biosafety cabinet (BSC), in a BSL-2 
or BSL-3 laboratory. In addition, all steps involving cultures, including plating, exami-
nation of plates/slants, subcultures, and manipulation of plates/slants/tubes, must be 
performed in a BSC and, ideally, in a laboratory meeting BSL-3 requirements (117). Vials 
placed into automated instruments can be handled safely outside a BSC until there is 
a need to remove aliquots of the broth, such as for stains, subcultures, and molecular 
assays. The risk assessment may determine if flagged positive vials may need to be 
transported using a leakproof container from room to room. A common question is 
whether AFB smears can be stained outside a BSC; the broad answer is “yes,” because 
once prepared and fixed, AFB smears do not aerosolize readily and thus pose little 
biological hazard to laboratory staff when stained outside a BSC. In addition, as noted 
by Chedore et al., chemical fixation with 5% phenol in ethanol is superior to heat 
fixation by passage through the blue cone of a flame of a gas burner (120). A risk 
assessment should be used to determine the best way to prepare and fix AFB smears 
for one’s laboratory. In the same way, examination of sealed tubes containing liquid 
media, sealed slants, sealed petri dishes, or petri dishes contained within sealed plastic 
bags can be done safely at the bench so long as BSL-2 conditions are met and a risk 
assessment has been conducted.
Several aspects particular to the Xpert assay suggest that it might present a very low 
risk to testing personnel (121). The Xpert assay starts with the addition of a highly 
tuberculocidal sample treatment reagent to each sputum sample (or concentrated 
sputum pellet). Used as recommended, the use of sample treatment reagent complies 
with international decontamination standards (122, 123), reducing the viability of M. 
tuberculosis bacteria in sputum by at least 6 log10 units after 15 min of incubation (124). 
Longer incubation periods appear to completely sterilize samples spiked with very high 
numbers of M. tuberculosis bacteria. After a 15-min incubation, the sputum sample 
treatment reagent mixture is transferred to a plastic assay cartridge, the cartridge lid is 
closed, and the cartridge is placed into an Xpert instrument. The remainder of the assay 
is performed within the closed cartridge. The use of a closed-cartridge system can 
potentially further reduce or eliminate the biohazard risk by performing sample pro-
cessing in an aerosol-resistant enclosure. The biosafety precautions for performing the 
Xpert assay are equivalent to the requirements for performing direct sputum AFB smear 
microscopy, i.e., minimal (125, 126).
Decontamination and Disposal of Laboratory Waste
The 2012 CDC guidelines for safe work practices for human and animal medical 
diagnostic laboratories (117) state the following regarding mycobacteriology laboratory 
waste. (i) Provide an autoclave in the mycobacteriology laboratory so that generated 
waste can be sterilized before transport from the laboratory. Adhere to the scheduled 
quality control and maintenance procedures for the autoclave. (ii) If an autoclave is not 
available or for items that cannot be autoclaved, all waste from the mycobacteriology 
laboratory must be securely contained in leakproof containers. Package waste so that 
the outside of the container can be disinfected before it leaves the laboratory. (iii) 
Chemically disinfect waste materials before removal from the BSC.
The decision as to how to handle waste is part of the risk assessment for the 
laboratory and will also be driven by the type of facility and the facility’s approach to
biohazard waste disposal (i.e., some facilities still autoclave all biohazard waste on site; 
others do not). It bears emphasizing that some types of biological waste cannot be 
autoclaved safely, the most common examples being waste containing bleach or 
phenolic compounds.
Disposal of all laboratory waste requires compliance not only with safety guidelines 
but also with federal regulations for protecting patient confidentiality, a task achieved 
primarily through compliance with the Health Insurance Portability and Accountability 
Act (HIPAA). Disposal of laboratory and other hospital/clinic waste poses unique 
challenges due to the presence of many types of labels attached to a wide variety of 
products. Typically, the removal of labels manually is not an option due to the time and 
effort required as well as the observation that parts of labels often remain attached to 
products. The most common approach is to use labels that darken during autoclaving, 
thereby obscuring the wording and numbering on labels. Several commercial vendors 
manufacture such heat-sensitive labels, but it is strongly recommended that each 
laboratory verify that these labels work as intended under local conditions.
WORK-UP OF SPECIMENS
This section addresses various aspects of the laboratory diagnosis of mycobacterial 
infections: acceptable specimens and rejection criteria, specimen processing, and 
media. The intent of this section is not to delineate specific protocols for processing but 
rather to provide overall principles regarding various aspects of laboratory diagnosis as 
well as other details to aid in protocol development.
Acceptable Specimens and Rejection Criteria
Most specimens sent to the laboratory that are acceptable for routine bacterial 
culture are also acceptable for processing for AFB; however, every laboratory should 
develop specific criteria for acceptance and rejection (1, 103, 115) to provide methods 
for the optimal isolation of Mycobacterium spp. Most specimens will be obtained from 
the respiratory tract, especially expectorated and induced sputum (the optimal volume 
is 5 to 10 ml), bronchial aspirates, and bronchoalveolar lavage fluids. Furthermore, the 
2017 ATS/IDSA/CDC TB diagnosis guidelines recommend that postbronchoscopy spu-
tum specimens be collected from all adults with suspected pulmonary TB who undergo 
bronchoscopy (98).
A systematic review by Ho et al. (127) found that microscopic sputum quality 
assessment and rejection criteria used for typical bacterial culture are not relevant to 
the assessment of sputum quality for AFB smear and culture. Designed to detect 
sputum contaminated with upper respiratory flora, the two criteria commonly used to 
assess sputum quality for bacterial culture, i.e., low numbers of sputum squamous 
epithelial cells and white blood cell/squamous epithelial cell ratios, were poor predic-
tors of M. tuberculosis-positive sputum. However, since the sputum decontamination 
process used before the inoculation of media for mycobacteria eliminates most con-
taminating organisms, the rejection of contaminated specimens by using these param-
eters confers no specific advantage.
Khan et al. (128) found that, despite being the least technical and time-consuming 
method, visual assessment to determine whether the specimen is sputum or saliva 
rejected the lowest proportion of AFB-positive specimens (0.3%). Most microscopic 
grading criteria, particularly those that considered the squamous epithelial cell count, 
rejected a large proportion of specimens (30 to 66%), a sizeable fraction of which 
contained AFB (6 to 12%).
Also acceptable for processing for AFB are body fluids such as urine; peritoneal, 
pleural, synovial, and pericardial fluids; and tissue biopsy specimens of lung, liver, and 
kidney, etc. Fluids, tissues, and lavage fluids (gastric and bronchoalveolar) are much 
better for AFB recovery than are specimens collected on swabs; swab specimens should 
be discouraged. Since the sensitivity of stool AFB smears is only 32 to 34%, AFB smear 
results should not determine whether a culture for mycobacteria is performed (129). 
The use of stool specimens from patients other than persons living with HIV should be
(iv) Samples are old, usually considered to be7 days from the date of collection (132).
(v) Sputum or urine is collected as a pooled specimen. (vi) The specimen is a formalin-
fixed tissue specimen for growth detection; however, it may be suitable for molecular
detection, especially when it is the only specimen type available (for detailed informa-
tion regarding collection and transport, storage conditions for specimens prior to
testing, as well as minimum volumes, see reference 132).
discouraged. Cerebrospinal fluid (CSF) is an acceptable specimen for mycobacterial 
processing provided that an adequate volume is obtained (5 to 10 ml is preferred). 
However, the incidence of mycobacterial meningitis is low, especially in high-income 
countries, and CSF culture for mycobacteria should be performed when the results of 
CSF chemistry tests and the CSF cell count and differential indicate possible infection 
with mycobacteria, i.e., high protein levels, low glucose levels, and the presence of 
lymphocytes (130, 131).
Processing of inappropriate clinical specimens for mycobacterial detection is a waste 
of both financial and personnel resources. Discussion with clinicians and other health 
professionals may be needed to explain why the rejection criteria need to be enforced. 
These criteria should be readily available online and in procedure manuals.
Before discarding any patient specimens, it is prudent to discuss the circumstances 
of suboptimal specimen collection for mycobacteria with the health care provider. In 
cases where the specimen is less common, involves an invasive procedure, or could not 
otherwise be easily re-collected, an exception to the rejection criteria may be justified. 
In addition to general criteria for specimen rejection (e.g., unlabeled or mislabeled 
specimens), rejection criteria for AFB smear and culture should include the following (1, 
132). (i) There are inadequate amounts of a specimen, e.g., 3 ml of sputum. (ii) The 
specimens are watery expectorated sputum that contains predominantly saliva (note 
that induced sputum may resemble saliva, and therefore, “induced sputum” should be 
specifically identified on the requisition form). (iii) Dry swabs (along with swabs in 
general) should be discouraged; however, the ESwab may be suitable for preserving the 
viability of Mycobacterium species (133). Preferred specimens for AFB recovery should 
be tissues and body fluids; swabs are not recommended for the isolation of mycobac-
teria, since they provide limited material. Swabs may be acceptable only if a specimen 
cannot be collected by other means, and a disclaimer should be included in the report.
Processing of Specimens for Mycobacterial Stains and Culture
Due to the lengthy incubation times required for the growth of most Mycobacterium 
spp., methods to eliminate non-AFB and fungi should be employed before plating of 
the specimens. Sterile tissues and body fluids may not need decontamination; however, 
sputum, bronchoalveolar lavage fluid, stool, urine, skin, and many other specimens that 
usually contain contaminating microbes need to be decontaminated to allow the 
growth of mycobacteria. The chosen decontamination process should not seriously 
affect the viability of mycobacteria. All samples, sterile and nonsterile, should also be 
concentrated to maximize the recovery of mycobacteria. For viscous specimens such as 
sputum, liquefaction is necessary, along with decontamination and concentration.
In its manual (134), the WHO Global Laboratory Initiative recommends the inclusion 
of one negative-control specimen (to control for cross-contamination) and one 
positive-control specimen (H37Rv or H37Ra, to verify the accuracy of the methods) 
weekly with the processing of a batch of clinical specimens. These control specimens 
must be included near the end of the batch and handled as patient specimens being 
processed for AFB smear microscopy and culture. However, the inclusion of a positive 
control in the processing of patient specimens is controversial and is discouraged in the 
United States due to the risk of cross-contamination (1).
Sterile specimens. Tissues can be ground with 0.85% sterile saline or 0.2% sterile 
bovine albumin and then inoculated into broth and solid media. Body fluids, e.g., CSF, 
pleural effusions, or ascites, should first be concentrated by centrifugation at 3,000  
g for 15 min prior to the inoculation of the resultant sediment. However, if the volume 
of body fluid submitted for culture is small and cannot be obtained again, i.e.,
TABLE 5 Digestion and decontamination methods for processing of AFB specimensa
Decontaminant(s) (reference) Indication(s)
NALC–2% NaOH (75) Decontamination of sputum and other nonsterile specimen types
Oxalic acid (75) Specimens known to be contaminated with Pseudomonas spp.; CF patients
NALC-NaOH and oxalic acid (2-step procedure) (137) Respiratory specimens from CF patients
Chlorhexidine (138) Respiratory specimens from children and adolescents with CF and from CF patients of
any age with suspected M. abscessus infections (may not be compatible with the
MGIT detection system)
Sulfuric acid (75) Urine that consistently yields a contaminated culture when processed with NALC-NaOH
aNALC, N-acetyl-L-cysteine; NaOH, sodium hydroxide; CF, cystic fibrosis.
irreplaceable, it may be added directly to liquid media (1). Sterile specimens should be 
transported to and processed in the laboratory as soon as possible. If transportation to 
the laboratory is delayed by more than 1 h from the time of collection, with the 
exception of blood and CSF, specimens should be refrigerated at 2°C to 8°C (135).
Blood collection tubes should contain sodium polyanethol sulfonate (SPS), heparin, 
or citrate anticoagulants and be transported expeditiously to the laboratory. EDTA 
tubes should not be used (1).
Nonsterile or contaminated specimens. Liquefaction of the specimen and decon-
tamination are essential for sputum and other respiratory tract specimens, stool, skin 
scrapings, and urine. It is important to mix the solution vigorously until it is liquefied 
(about 5 to 20 s on a test tube mixer) and to invert each tube to ensure that the solution 
contacts all inside surfaces of the tube and cap. One of the most common decontami-
nants is sodium hydroxide (NaOH), which also serves as a mucolytic agent; however, 
NaOH can also be detrimental to mycobacteria unless it is used with caution regarding 
the concentration and time of exposure. More commonly, laboratories use a combina-
tion of liquefaction and decontamination using N-acetyl-L-cysteine (NALC) to liquefy 
the specimen without harming the bacterial cells, in conjunction with NaOH at a lower 
concentration than would be used with NaOH alone. The most commonly used 
combination is NALC–2% NaOH. Concentrations of up to 5 to 6% NaOH can be utilized 
for heavily contaminated specimens, although up to 90% of the mycobacteria may also 
be harmed (1). There are other decontamination agents used for specific specimen 
types, e.g., urine, and/or known patient diseases, e.g., CF (see Table 5 for a summary of 
the various decontaminating agents).
Nonsterile specimens should be transported to the laboratory and processed as 
soon as possible. If transportation to the laboratory is delayed by more than 1 h from 
the time of collection, specimens should be refrigerated at 2°C to 8°C (135).
There are some special considerations for selected specimens. Gastric lavage fluid 
should be processed within 4 h of  collection or neutralized with 10% sodium bicar-
bonate and then refrigerated if further processing is delayed (75). Urine can be 
distributed in up to four 50-ml conical tubes, and the sediments can be combined; up 
to 1 g of formed stool samples should be emulsified in saline and thoroughly vortexed, 
and the particles should be allowed to settle out before processing the top portion of 
the liquid (1).
Attempting to recover NTM from a respiratory specimen obtained from a CF patient 
is challenging for the laboratory (136). Approximately 50% to 70% of respiratory 
specimens from CF patients contain Pseudomonas aeruginosa, which is resistant to 
NALC-NaOH decontamination; thus, after decontamination with NALC-NaOH, specimen 
contamination rates of between 35% and 70% occur. When a second step using 2.5%
oxalic acid is added, the contamination rate is reduced to 3% to 5%, although low 
numbers of MAC bacteria may not be recovered (137). Chlorhexidine alone has been 
shown to be an effective means of decontaminating CF respiratory specimens by using 
solid media (138). As an added value, pretreatment of sputum from CF patients with 
chlorhexidine yielded twice as many NTM-positive cultures as specimens treated with 
NALC-NaOH (136). Chlorhexidine, which is potentially toxic to mycobacteria, must be 
inactivated by incorporation with egg lecithin in the culture medium. Asmar et al. (139)
TABLE 6 Various types of media used in the mycobacteriology laboratorya
Mediumb Description
Solid egg based (supports good growth of
most mycobacteria)
LJ Good for M. tuberculosis complex; inferior for NTM recovery; although CO2 is not essential
to initiate growth, it stimulates earlier and more luxuriant growth
Gruft modification of LJ Contains antibiotics (penicillin and nalidixic acid) that may be useful to control excessive
contamination; although CO2 is not essential to initiate growth, it stimulates earlier and
more luxuriant growth
Agar based (less contamination due to more
simple formulation and thus less likely
to support growth of contaminants)
Middlebrook 7H10 Transparent, so colonies can be more easily observed; requires incubation with 5 to 10%
CO2 for maximum yield
Middlebrook 7H11 7H10 agar enriched with casein digest; transparent, so colonies can be more easily
observed; requires incubation with 5 to 10% CO2 for maximum yield; stimulates more
luxuriant growth of drug-resistant M. tuberculosis complex bacteria
Mitchison’s selective 7H10 and 7H11 Contain the antibiotics carbenicillin, polymyxin B, trimethoprim lactate, and amphotericin
B; suppressive for most contaminants; McClatchy et al. found higher yield of
mycobacteria on selective 7H11 medium than on nonselective 7H11 mediumc; can be
used in conjunction with nonselective media to increase culture yields
TLA system Thinly poured plates of Middlebrook 7H11 agar; microcolonies can be detected and
work-up can be started earlier than with traditional solid media; this method can be
labor-intensive, but for laboratories that cannot afford automated broth detection
systems, the time to detection with TLA is equivalent, without the expense of an
instrument
aSee references 75 and 335.
bLJ, Löwenstein-Jensen; TLA, thin-layer agar.
cSee reference 336.
demonstrated the superiority of a chlorhexidine decontamination procedure combined 
with a new agar medium, MOD9, compared to NALC-NaOH and MGIT960 for the 
isolation of M. tuberculosis.
Media
A combination of broth and solid media should be included for inoculation. Broth 
medium is essential for the recovery of Mycobacterium spp. in as short an incubation 
time as possible. There are many types of broth media, many of which are included with 
automated mycobacterial detection systems; most are based on Middlebrook 7H9 
broth. Solid media (egg based and non-egg based) are included to ensure the recovery 
of rare strains that may not grow in broth. Table 6 lists the various types of media that 
are available, while Table 7 summarizes salient features of automated broth-based 
culture systems. Of significance, some decontamination/concentration procedures are 
known to be compatible with egg-based media only and may not be used with any 
other media not containing egg yolk. These procedures include the use of Zephiran-
trisodium phosphate (Z-TSP), sodium lauryl sulfate, cetylpyridinium chloride, or other 
quaternary ammonium compounds (140).
Tubed media should be incubated in a slanted position with screw caps loose for at 
least 1 week to ensure an even distribution of the inoculum (75). Thereafter, if space is 
needed, tubes may be placed upright with the caps tightened to minimize evaporation 
and drying of media. Plated medium, ideally placed into CO2-permeable plastic bags or 
sealed with CO2-permeable tape, should be incubated with the medium side down if 
all the inoculum has not been absorbed (75).
For the isolation of mycobacteria, the use of a liquid medium in combination with 
at least one solid medium is essential for good laboratory practice (141). Broth medium 
allows the more rapid growth and detection of mycobacteria and, therefore, the more 
rapid detection of the M. tuberculosis complex than does solid medium.
Specifically with respect to cultures of respiratory specimens from CF patients, it was 
recently reported that M. abscessus and its subspecies as well as other rapidly growing 
mycobacteria can be recovered on a medium that is routinely used for the isolation of
TABLE 7 Continuously monitored broth culture instrument systemsa
System(s)b Descriptionc Advantage and limitation(s) (reference)
BD Bactec MGIT automated mycobacterial
systems (960 and 320 systems,
depending on vol; BD Diagnostic
Systems, Sparks, MD)
System automatically detects tube placement, i.e.,
scan-and-load technology; uses MGIT medium
containing patented sensors that detect
oxygen consumption, indicating mycobacterial
growth; PANTA antibiotic mixture is added to
the MGIT tube prior to inoculation; a
fluorescent compound, embedded in silicone in
the tube bottom, is quenched by the presence
of oxygen, but when the oxygen is
metabolized by mycobacteria or another
microorganism, the compound fluoresces
Time to detection is much shorter with this system
than with solid media; mycobacterial growth,
including M. tuberculosis complex, M. xenopi, and
various other NTM, can go undetected by the
instrument (337); tubes should be visually
inspected for clumps before the tubes are
discharged as negative (338)
BacT/Alert Mycobacteria detection system
(bioMérieux, Durham, NC)
Utilizes a colorimetric sensor and reflected light
to monitor the presence and production of
CO2; the sensor changes color because of CO2
produced by the metabolic activity of
mycobacteria and other microorganisms;
enrichment fluid containing bovine serum
albumin, sodium chloride, oleic acid, and
saponin is added; bottles contain antibiotic
mixture of amphotericin B, azlocillin, nalidixic
acid, polymyxin B, trimethoprim, and additional
growth factors
Time to detection is much shorter with this system
than with solid media; mycobacterial growth can
go undetected by the instrument; tubes should
be visually inspected for clumps before the
tubes are discarded as negative; negative
cultures may also be checked by AFB smear
and/or subcultured at some point prior to
discarding the specimen as negative (339)
VersaTREK (ThermoFisher Scientific,
Waltham, MA)
Bottles contain antibiotic mixture of polymyxin B,
vancomycin, nalidixic acid, and amphotericin B;
each bottle is continuously monitored for
changes in gas pressure, due to consumption
of oxygen by mycobacteria and production of
gas by their metabolic activity
Time to detection is much shorter with this system
than with solid media; at the end of the
incubation period, a bottle not exhibiting a
positive growth response should be visually
inspected for turbidity (340)
aMycobacterial blood culture methods in common use include visual inspection of processed blood (e.g., Isolator-10 system; Inverness Medical, Princeton, NJ)
inoculated on solid medium, continuous detection in liquid medium inoculated with blood (e.g., BacT/Alert MB system or Bactec Myco/F Lytic system) (341), or
processed blood (e.g., VersaTREK) (340). The turnaround times to detection for M. tuberculosis were 23.8 days for the Isolator-10 system, 20.0 days for the Myco/F
Lytic system, and 16.5 days for BacT/Alert MB (341).
bSee reference 1.
cPANTA, polymyxin B, amphotericin, nalidixic acid, trimethoprim, and azlocillin.
bacteria from CF patients, Burkholderia cepacia selective agar (BCSA) (142, 143). M. 
abscessus clinical isolates were recovered on BCSA from 65% to 75% of infected 
individuals, whereas these organisms were recovered from 85% of patients by using 
mycobacterium-specific culture methods. In addition, incubation of BCSA plates for 14 
days greatly enhanced recovery compared with a 5-day incubation (142). More recently, 
a newly developed medium, namely, RGM, was introduced for the isolation of rapidly 
growing mycobacteria from the sputum of CF patients without the need for decon-
tamination of specimens (143–146). RGM supported the growth of all mycobacteria 
tested and was more selective than BCSA (144).
NUCLEIC ACID AMPLIFICATION TESTS
Diagnostic
Algorithms for testing specimens from patients suspected of having TB should 
include a NAAT. Guidelines from the CDC recommend the performance of a TB NAAT 
on at least one respiratory specimen from patients with signs and symptoms consistent 
with pulmonary TB. This is especially important if a diagnosis of TB has not yet been 
made and the test result would alter patient care and/or TB control activities (106). 
Based on CDC guidelines, an institution may want to develop criteria to identify 
patients suspected of having TB. Although the preference is to test the first collected 
specimen by a NAAT to decrease the time to a result, an AFB smear-positive specimen 
should take priority due to the increased sensitivity of NAATs for these specimens. It is 
important to note that NAATs should not replace or delay routine microbiological 
methods, including AFB smear. The NAAT should ideally be performed on all first-time
TABLE 8 Characteristics of FDA-cleared and FDA-market-authorized NAATs for M. tuberculosis complex detection according to the
manufacturers’ package insertsb
Test Specimen types Methodology
Sensitivities (%) Specificity (%)
Tests for
inhibitors
AFB smear
negative
AFB smear
positive
AFB smear
negative
AFB smear
positive
Hologic Amplified
MTD
AFB smear-positive and
-negative
concentrated
sediments prepared
from sputum,
bronchial specimens,
or tracheal aspirates
Transcription-mediated
amplification of rRNA and
detection by hybridization
protection assay
64.0 for single
specimen,
71.4 for 2
specimens
87.5 for single
specimen,
100 for 2
specimens
99.1–100 100 Noa
Cepheid Xpert
MTB/RIF
AFB smear-positive and
smear-negative
sputum samples or
concentrated
sediments prepared
from sputum
Real-time PCR using molecular
beacon probes to the 81-bp
rifampin resistance-
determining region of rpoB
73.1 for single
specimen,
90.0 for 3
specimens
97.8 for single
specimen,
99.5 for 3
specimens
97.9–99.0 97.9–99.0 Yes
aCan be assessed with additional steps.
bSee references 147 and 148. AFB, acid-fast bacilli.
patients with suspected TB, and results should be reported within 48 h of specimen 
receipt (106).
There are two commercial NAATs for the detection of M. tuberculosis complex DNA 
directly from respiratory specimens: the MTD test and the FDA-market-authorized Xpert 
test. There are also many laboratory-developed NAATs being used in clinical and public 
health laboratories. Xpert is authorized for use with AFB smear-positive and AFB 
smear-negative expectorated and induced raw sputum specimens as well as processed 
sputum sediment, and the MTD test is approved for both AFB smear-positive and AFB 
smear-negative respiratory specimens (147, 148). Although the specificity of NAATs for 
TB diagnosis is very high, the sensitivities vary widely and depend on both the AFB 
smear status of the specimen (positive or negative) and the specimen type (147, 148). 
Table 8 summarizes the claims and performance characteristics of these two commer-
cial assays.
NAATs may need to be modified and validated for off-label use for other specimen 
types with the caveat that the test performance may be different. It is important to 
determine the best NAAT for the patient population served by the laboratory and 
whether NAATs will be performed on respiratory specimens only or whether nonrespi-
ratory specimens will also be validated and tested. An additional consideration is 
whether NAATs will be performed on at least one specimen from individuals who are 
first-time TB-suspect patients or whether testing will include only AFB smear-positive 
specimens. For example, if the NAAT is performed on AFB smear-positive specimens 
only, it will be performed on a concentrated, processed specimen after an AFB smear 
result is available. In the ideal algorithm, a NAAT is performed irrespective of the AFB 
smear result, and therefore, the specimen can be tested as soon as it is received, with 
results being available sooner. If a NAAT is not offered by the laboratory, the specimen 
should be sent to a reference laboratory or to a state or local public health laboratory 
(see Table 9 for recommendations for interpretation of NAAT results).
Disadvantages of the molecular detection of the M. tuberculosis complex directly 
from clinical specimens include the inability to differentiate among species within the 
M. tuberculosis complex. In addition, a positive NAAT result does not differentiate 
between live and dead organisms. For this reason, amplification technologies should 
not be used on specimens collected from patients who have received antituberculosis 
drugs for more than 7 days or have received such therapy in the last 12 months prior 
to collection (148, 149). Furthermore, approximately 4% of pulmonary and 19% of 
extrapulmonary specimens have substances that are inhibitory to amplification (deter-
TABLE 9 CDC recommendations for interpretation of results of tuberculosis nucleic acid amplification tests on respiratory specimensa
AFB smear result TB NAAT result Interpretation
Positive Positive Presumed pulmonary TB
Begin anti-TB therapy while awaiting culture and susceptibility results
Negative Positive Consider performing NAAT on a second specimen to confirm results
Consistent with pulmonary TB but less infectious than AFB smear-positive TB
Use clinical judgment regarding beginning anti-TB therapy
Positive Negative Rule out inhibition by using an internal amplification control
Test additional specimen(s) by NAAT
Consistent with the presence of NTM if all NAAT results are negative
Use clinical judgment regarding beginning anti-TB therapy
Negative Negative Rule out inhibition by using an internal amplification control
Multiple negative AFB smears and multiple negative NAAT results, in combination with
other requirements, support discontinuation of airborne isolation
Use clinical judgment regarding beginning anti-TB therapy
aSee references 105, 106, and 342.
mined by a failed internal amplification control), making negative test results invalid 
(149). Since it is rare that all specimens from a given patient show inhibition, testing of 
multiple samples can be advantageous (150).
Detection of Antimicrobial Resistance
Due to the slow growth of the M. tuberculosis complex, molecular techniques are 
well suited not only to detect the M. tuberculosis complex directly from patient 
specimens but also to screen for mutations associated with antimicrobial resistance. 
Although Xpert is the only FDA-cleared product for the detection of RIF drug resistance 
in TB isolates in the United States, several assays have received a CE mark for clinical use 
in Europe. These assays include the Genotype MTBDRplus Version 2 system (Hain 
Lifescience, Germany) to detect RIF and INH resistance; the Autoimmun Diagnostika 
GmbH (Strasberg, Germany) TB Isoniazid, Rifampin assay; and the Innogenetics (Ghent, 
Belgium) INNO-LiPA Rif.TB assay. All these systems detect RIF resistance, since a main 
cause for treatment failure and fatal clinical outcome in TB patients is resistance to 
rifampin (346). In addition, RIF resistance can be a marker for MDR-TB in the appropriate 
setting (151).
RIF has long been used in combination first-line therapy for TB. The cellular target 
of RIF is the beta-subunit of bacterial DNA-dependent RNA polymerase, which is 
encoded by the rpoB gene. Point mutations in rpoB can render the organism resistant 
to RIF due to decreased binding affinity and can result in high-level resistance (152). RIF 
resistance is detected by analyzing the rpoB gene for specific mutations in the 81-bp RIF 
resistance-determining region (RRDR). The Xpert assay includes five probes that hy-
bridize to the RRDR of the M. tuberculosis complex. RIF resistance is reported if at least 
one probe does not produce a signal (indicating a mutation at the hybridization site 
preventing hybridization) or if there is a 3.5-cycle difference between probe signals 
(indicating less efficient hybridization due to mutation) (147). Compared to the use of 
three sputum cultures per patient, the Xpert assay performed with 96.1% sensitivity and 
98.6% specificity during a clinical trial (147, 151). However, the sites in the clinical trial 
(Peru, Azerbaijan, South Africa, and India) have a higher prevalence of TB and MDR-TB 
than the United States. Therefore, the positive predictive value is likely to be lower in 
the United States. Of note, a positive RIF result by Xpert can be obtained for synony-
mous (i.e., silent) mutations. For these reasons, it is critical that initial RIF resistance 
results be confirmed by traditional (i.e., phenotypic) AST. Additional molecular confir-
mation of results can also be rapidly obtained through the CDC’s MDDR service (153). 
A summary of the CDC’s recommendations for the interpretation of RIF resistance 
molecular assay results obtained by the Xpert test is presented in Table 10, but these 
recommendations also apply to other molecular detection assays as well.
TABLE 10 CDC recommendations for interpretation and reporting of positive Xpert resultsa
Xpert result Interpretation Suggested minimum reporting language
M. tuberculosis complex detected M. tuberculosis complex DNA is detected in
the sample
M. tuberculosis complex detected
Rifampin resistance detected Mutation(s) is detected in rpoB A mutation in rpoB has been detected, indicating possible
rifampin resistance; confirmatory testing should follow
M. tuberculosis complex detected M. tuberculosis complex DNA is detected in
the sample
M. tuberculosis complex detected
Rifampin resistance not detected Mutation(s) is not detected in rpoB No rpoB mutations detected; probably rifampin susceptible
M. tuberculosis complex detected M. tuberculosis complex DNA is detected in
the sample
M. tuberculosis complex detected
Rifampin resistance indeterminate Mutation(s) in rpoB could not be
determined due to insufficient signal
Presence of rpoB mutations cannot be accurately determined
aAdapted from reference 342.
For the molecular detection of high-level INH resistance, the katG gene (coding for 
the catalase peroxidase) is examined, and for the detection of low-level INH resistance, 
the promoter region of the inhA gene (coding for the NAD [NADH] enoyl-acyl carrier 
protein reductase) can be analyzed. The recognition of these two loci is of clinical 
significance. In the presence of inhA mutations, INH resistance can usually be success-
fully controlled with high-dose INH therapy (154). The presence of an inhA mutation 
may also alert the clinician to not include ethionamide or prothionamide in the MDR-TB 
treatment regimen due to potential cross-resistance to these agents (115). The assump-
tion that RIF-susceptible cases tested by the Xpert assay would also be INH susceptible 
is not necessarily true. In a study from Mumbai, India, by Vadwai et al. (155), 8.7% of TB 
patients tested by the Xpert assay were negative for RIF resistance; however, they 
demonstrated INH monoresistance phenotypically. This significant number of patients 
with INH-resistant TB, if remaining unidentified, will be treated with only a single active 
drug during the continuation phase of their therapy, which will inevitably lead to 
MDR-TB. These few points highlight the importance of molecular INH resistance 
screening (156).
Although several reports have described the molecular detection of RIF and/or INH 
resistance utilizing line probe, real-time PCR, or sequencing methodologies, it should 
be noted that conventional AST is still the reference method due to incomplete data on 
all mutations and/or target genes associated with phenotypic resistance. Therefore, the 
most appropriate use for the molecular detection of antimicrobial resistance is as an 
initial screening assay. This approach could potentially identify resistant isolates weeks 
earlier, allowing clinical care to be significantly improved.
Infection Control
In February 2015, the FDA cleared the Xpert assay to aid physicians in determining 
if patients with suspected TB can be removed from airborne infection isolation (AII)
(157, 158). In a consensus statement by the U.S. National TB Controllers Association and 
the U.S. Association of Public Health Laboratories, it is noted that the process described 
here is not to be used alone to rule out TB; Xpert test-negative or AFB smear-negative 
sputum may contain viable organisms and represent infectious TB (160). Based on an 
international clinical trial (multiple U.S. sites, South Africa, and Brazil), one or two 
negative tests performed on respiratory specimens from patients with signs and 
symptoms of pulmonary TB may allow the patient to be removed from AII (159). This 
study included 219 subjects with culture-confirmed M. tuberculosis complex infection 
out of 992 total subjects (22%), 45% of whom were persons living with HIV. The 
performance of a single Xpert test detected 97% of patients who were AFB smear 
positive and had culture-confirmed M. tuberculosis complex infection, while the per-
formance of two Xpert tests detected 100% of these patients. The use of one or two 
Xpert tests detected 55% or 69%, respectively, of sputum specimens from AFB smear-
negative but culture-positive patients. Prior to the clearance of this indication by the 
FDA, removal from AII relied primarily on AFB smear results from three specimens
obtained at least 8 h apart. Studies have shown that the use of the Xpert test allowed 
the release of patients from AII earlier and can result in health care cost savings (161, 
162). The decision of whether to use one or two Xpert tests to remove patients from AII 
should be based on clinical circumstances, institutional guidelines, and state require-
ments. Clinical decisions regarding the need for continued AII should be made in 
conjunction with other clinical and laboratory data and not based solely on negative 
Xpert results (158).
SMEAR MICROSCOPY AND GROWTH DETECTION OF ACID-FAST BACILLI
Because of their unusual outer cell wall structure that contains mycolic residues of 
peptidoglycolipids, mycobacteria resist decolorization by acidified alcohol after the 
application of certain arylmethane dyes such as basic fuchsin, in which stable com-
plexes are formed between the mycobacteria and dye (163). Thus, mycobacteria can be 
distinguished from other bacteria by AFB smear microscopy. This key property of the 
mycobacterial cell wall is referred to as acid fastness.
Diagnostic AFB Smear and Growth Detection
Despite major advances in the diagnosis of mycobacterial infections, microscopic 
examination for AFB remains a primary tool because it identifies highly infectious AFB 
smear-positive cases, is rapid, and is inexpensive; its ease of preparation and availability 
make it particularly attractive in most global settings (specific aspects regarding AFB 
smear microscopy in middle- and low-resource settings are addressed in Resource-
Limited Settings, below). Although it has been reported to have more than 80%
sensitivity compared with culture for identifying cases of pulmonary TB in some 
settings, the sensitivity has also been reported to be lower and variable in other 
settings (164); of note, AFB smear microscopy is of limited utility for paucibacillary 
disease such as in pediatric patients, persons living with HIV, and those with extrapul-
monary infections. For the initial diagnosis of pulmonary TB, one should collect a series 
of three sputum specimens, 8 to 24 h apart, at least one of which is an early-morning 
specimen (105).
The optimum number of sputum specimens to establish a diagnosis has been 
examined in several studies that have served to support recommendations to decrease 
the minimum number of sputum specimens examined from 3 to 2, assuming that they 
are examined in a quality-assured laboratory. In a systematic review of 37 studies on the 
yield of sputum AFB smear microscopy (165), it was found that, on average, the initial 
specimen was positive in 85.8% of all patients ultimately found to have AFB detected, 
the second specimen was positive in an additional 11.9% of patients, and the third 
specimen was positive in a further 2.3% of patients. In studies that used culture as the 
reference standard, the mean incremental yield in sensitivity of the second specimen 
was 11.1%, and that of the third specimen was 3.1%. Thus, it appears that in a 
diagnostic evaluation for TB, at least two specimens should be obtained. In some 
settings, because of practicality and logistics, a third specimen may be useful, but 
examination of more than two specimens adds minimally to the number of positive 
specimens obtained.
AFB Smear and Growth Detection for Patient Management
Sputum specimens for AFB smear and culture should be obtained monthly until two 
consecutive specimens are negative upon culture (166). Collection of sputum speci-
mens more often early in treatment for assessment of the treatment response and at 
the end of treatment is optional. If the patient remains culture positive after completing 
3 months of treatment, AST should be repeated. The duration of the continuation-
phase regimen hinges on the microbiological status at the end of the intensive phase 
of treatment; thus, obtaining a sputum specimen at the time of completion of 2 months 
of treatment is critical if sputum culture conversion to a negative result has not already 
been documented. The culture result of a sputum specimen obtained at the comple-
tion of the intensive phase of treatment (2 months) has been shown to correlate with
the likelihood of relapse after the completion of treatment for pulmonary TB albeit with 
low sensitivity. In patients treated for 6 months, having both cavitation on the initial 
chest radiograph and a positive culture at the completion of 2 months of therapy have 
been associated with rates of relapse of approximately 20%, compared with a rate of 
2% among patients with neither factor.
In addition, the AFB stain can be used to confirm growth from various clinical 
specimens and can be used to release a patient from isolation after obtaining 3 
negative AFB smears of sputum collected 8 h apart, one of which is an early-morning 
specimen (105). Although it is believed by some clinicians and investigators that there 
was a difference in staining of AFB when testing nonviable mycobacteria with carbol 
fuchsin-based stains versus fluorescence-based stains, Truant et al. (167) reported no 
major differences in staining characteristics with either heat-killed or antibiotic-killed 
AFB and viable AFB. Thus, an AFB smear alone cannot be used to determine the 
prestain viability of mycobacteria.
AFB Smear Preparation, Fixation, Staining, and Examination
Smears for AFB staining are best prepared from the sediment of specimens that 
have been liquefied, decontaminated, and concentrated by centrifugation. Inactivation 
of AFB smears that contain M. tuberculosis complex isolates for microscopy before the 
removal of the material from a BSC is an important safety factor in preventing the 
potential transmission of TB to technical staff. Heat fixing is one option, with the use of 
a slide warmer at 65°C to 75°C for at least 2 h once the slides are air dried (75). 
Alternatively, Chedore et al. (120) demonstrated that treatment with 5% phenol in 
ethanol for 5 min successfully fixed and inactivated all AFB smears containing M. 
tuberculosis complex isolates, both from concentrated sputum samples and from 
culture material. This chemical fixation protocol has the advantage of shortening 
turnaround times by 2 h for reporting AFB smear results.
Examination of two AFB smears will detect most AFB smear-positive cases. Testing 
of additional specimens provides only a marginal improvement in sensitivity (exami-
nation of a third sputum specimen increased the sensitivity between 2% and 5%) (164, 
168). The efficiency of the concentration techniques used directly affects the sensitivity 
of the AFB smear. A systematic review of 83 studies demonstrated that sputum treated 
with bleach or NaOH and concentrated by centrifugation is, on average, more sensitive; 
however, the data were insufficient to conclude whether the gain in sensitivity would 
apply to persons living with HIV (168). Essentially, three major protocols are widely used 
for AFB smears: Ziehl-Neelsen and Kinyoun methods use carbol fuchsin as the primary 
stain, with subsequent examination by using light microscopy, while a third method 
uses a fluorescent dye, auramine O, alone or with rhodamine, with subsequent exam-
ination by fluorescence microscopy. Researchers from Johns Hopkins University eval-
uated a more rapid, commercially available auramine O stain that may be more 
cost-effective and efficient (169). A systematic review (164) showed that the sensitivity 
of fluorescence microscopy was 10% higher than that of conventional carbol fuchsin-
stained sediments. In addition, it has been documented that the Kinyoun method of 
staining is less sensitive than Ziehl-Neelsen or fluorescent AFB staining (170). One 
hundred sixty-seven laboratories participated in a per-laboratory comparison of results. 
A comparison of prestained Ziehl-Neelsen versus prestained Kinyoun smears for the 
evaluation of differences in reading capabilities of participants revealed a significantly 
better performance of the Ziehl-Neelsen staining method (P  0.01) (170). Similar 
results as to the lack of sensitivity of Kinyoun staining compared to routine, hot 
Ziehl-Neelsen staining under field conditions have also been reported (171).
Because acid-fast artifacts may be present in the AFB smear, morphology must be 
examined closely for the presence of long and typically slender acid-fast rods or 
coccobacilli that may appear slightly curved, beaded, isolated, in pairs, or in groups and 
stand out clearly against the background. Using auramine O stain, acid-fast organisms 
stain yellow-green (if auramine and rhodamine are used, AFB will fluoresce orange-
yellow). Depending on the mycobacterial species, different morphologies may be
TABLE 11 Interpretation of AFB smearsa
No. of AFB seen by carbol fuchsin
stain at magnification of 1,000
No. of AFB seen by fluorescent stain
at magnification ofb: Interpretation according to:
250 450 CDC WHO
0/smear 0/smear 0/smear No AFB seen No AFB seen
1–2/300 fields 1–2/30 fields 1–2/70 fields Doubtful; repeatc Confirmation requiredd
1–9/100 fields 1–9/10 fields 2–18/50 fields 1 Scanty
1–9/10 fields 1–9/field 4–36/10 fields 2 1
1–9/field 10–90/field 4–36/field 3 2
9/field 90/field 36/field 4 3
aSee references 75 (CDC) and 177 (WHO). AFB, acid-fast bacilli.
bIf using a different magnification, interpretations must be adjusted.
cAlthough counts of 3 AFB per 100 fields are not considered positive, a second AFB smear from the same sample may be stained and examined, or another
specimen should be requested.
dConfirmation by another technician or by preparing, staining, and reading another AFB smear is required.
observed on stained AFB smears. For example, when stained from liquid medium, M. 
tuberculosis often demonstrates cording. Some NTM species can exhibit cording as well, 
albeit rarely, such as the MAC, M. kansasii, M. gordonae, M. chelonae, and M. marinum 
(172–174). NTM are often pleomorphic, sometimes appearing as long filaments or 
coccoid forms. An often challenging group of mycobacteria with respect to AFB stains 
is rapidly growing mycobacteria. These organisms may not always be acid fast with 
carbol fuchsin (1), auramine O (175), or auramine-rhodamine stain (175).
Of note, it is currently recommended that all positive AFB smears be confirmed 
either by a second reader, by restaining the slide (if a fluorescent stain was used) using 
a Ziehl-Neelsen stain, or by initially preparing two AFB smears, one for the fluorescent 
stain and the other for the Ziehl-Neelsen stain, in the event of a positive fluorescent AFB 
smear (132).
In general, with M. tuberculosis complex infections, the sensitivities of AFB smears 
vary due to a number of factors, such as the specimen type, the prevalence and severity 
of disease, the quality of specimen collection, the number of organisms in the speci-
men, and laboratory processing and staining procedures (170). Importantly, strict 
adherence to staining procedures, training and experience of laboratory personnel, and 
intermittent shedding of AFB can all impact the sensitivity of AFB smears. In general, if 
a patient is suspected of having pulmonary TB, a series of two or more sputum 
specimens with negative AFB smears makes this diagnosis very unlikely (115, 176, 177).
Interpretation and Reporting of Acid-Fast Smear Results
When acid-fast organisms are observed on an AFB smear, results must be quantified 
to be meaningful. Because this quantitation estimates the number of bacilli being 
excreted, the extent of a patient’s infectiousness can be assessed for clinical and 
microbiological purposes. A positive AFB smear is reported by the laboratory, as are the 
staining method employed and the quantity of organisms. Recommended interpreta-
tions of and ways to report results are shown in Table 11.
Growth Detection
Solid mycobacterial cultures are generally held 6 to 8 weeks, and protocols for liquid 
media usually require a minimum of 6 weeks of incubation before cultures can be 
discarded as negative (1). Specimens with positive AFB smears that are culture negative 
should be held an additional 4 weeks. Culture-negative specimens that are positive for 
mycobacteria by one of the NAATs or for cases with a high suspicion of TB should also 
be held an additional 4 weeks (1).
In 2012, the CDC conducted a multicenter study to determine whether M. tubercu-
losis complex cultures in automated broth-based systems could reliably be considered 
negative sooner than 6 weeks (178). For laboratories using standard processing pro-
cedures, 100% of M. tuberculosis complex isolates were detected from initial and 
follow-up specimens in 28 and 35 days, respectively, and no yield of M. tuberculosis
complex bacteria on solid or MGIT liquid medium was observed after 5 weeks. Receipt 
of interim negative reports earlier than 6 weeks could assist clinicians in considering 
alternative diagnoses and could alter the timing and prioritization of public health 
interventions. According to the CDC study, laboratories using MGIT liquid medium 
could issue reports of no growth of M. tuberculosis complex bacteria on initial speci-
mens as early as 4 weeks and, for patients undergoing treatment, as early as 5 weeks 
postinoculation. However, laboratories should analyze their own time-to-detection data 
to make informed protocol decisions.
Since many mycobacteria are slowly growing organisms, cultures can be examined 
for colony formation less frequently than routine bacterial cultures. All solid media 
should be examined within 3 to 5 days after inoculation to determine if there is 
contamination. In general, cultures should be examined twice per week for the first 2 
weeks and then at weekly intervals. Liquid medium systems read cultures continuously 
and provide an alert when the culture turns positive for growth (1); however, MGIT 
tubes may be inspected manually, daily for up to 2 weeks and twice weekly or weekly 
thereafter (1).
Irrespective of the growth media, the acid fastness of the growth should be 
determined by AFB staining. Also, it is advisable to subculture the broth on a blood or 
chocolate agar plate to rule out contamination. Once growth is detected and confirmed 
as AFB, identification methods are performed (see Identification, below). AST can then 
be performed (1) (see Antimicrobial Susceptibility Testing, below). Positive cultures may 
be kept at temperatures of up to 35°C to 37°C for several weeks. The CLSI recommends 
that isolates needed for possible follow-up be frozen at 80°C (132).
IDENTIFICATION
Molecular Identification of Cultured Organisms
The molecular techniques used for the identification of mycobacterial organisms 
cultured from patient specimens include direct probe hybridization and sequence-
based techniques. Probes are single-stranded oligonucleotides that can have various 
sizes but are generally less than 50 bp. Probe specificity is defined by the nucleic acid 
sequence of the probe. rRNA is a common target for identification by probes due to the 
relatively high copy number of rRNA in bacteria, thus increasing the sensitivity of 
detection. Furthermore, rRNA sequences contain conserved regions in addition to 
hypervariable regions, allowing the level of identification to be varied depending on 
the probe sequence. Commercially available probes for culture confirmation include 
those for the M. tuberculosis complex, M. avium, M. intracellulare, the MAC, M. gordonae, 
and M. kansasii (AccuProbe; Hologic, San Diego, CA). Although probe-based detection 
and identification methods are more expensive than conventional culture and identi-
fication methods, they have increased accuracy and decreased turnaround times 
relative to conventional biochemical methods (179). However, both false-negative and 
false-positive results may occur. Bacterial strains may possess polymorphisms that 
prevent hybridization (180, 181), or there may be similar sequences among strains that 
result in cross-reactivity (182, 183). Additional disadvantages are the limited number of 
commercial probes available and the inability to probe clinical specimens directly. 
Although probes are not FDA cleared to detect and identify mycobacteria directly from 
MGIT broth, some laboratories have validated probes for this. Somoskovi et al. dem-
onstrated 95.7% accuracy in identifying the M. tuberculosis complex when probes were 
used directly on positive MGIT broth cultures (184).
Line probe assays are available for certain NTM species, but they are not FDA cleared 
or FDA approved. Such tests include the INNO-LiPA Mycobacteria v2 assay (Fujirebio 
Europe, formerly Innogentics, Ghent, Belgium), GenoType CMdirect, GenoType NTM-
DR, GenoType Mycobacterium CM, GenoType Mycobacterium AS (Hain Lifescience), 
Speed-oligo Mycobacteria (Vircell, Granada, Spain), and Nipro NTMMDRTB detection 
kit 2.
In many larger laboratories, sequence-based identification has become a primary 
method to rapidly identify mycobacteria. This procedure can reduce the time to
identification over those of conventional methods, but initial growth of an isolate is still 
required prior to identification by sequencing. Sequencing may also be performed 
directly from a positive MGIT broth culture, but careful validation is required, and 
results should always be correlated with growth obtained from subculture. There are 
many targets used for sequence-based identification, but the 16S rRNA gene remains 
the most common target. The 16S rRNA gene encodes the highly conserved rRNA 
associated with the small subunit of the ribosome and is often used for taxonomic 
purposes and species identification. While 16S rRNA is highly conserved among bac-
teria, there are nucleotide variations concentrated in specific regions that are unique to 
each species. The entire gene is 1,550 bp, including the conserved and variable regions, 
but a discriminatory sequence can generally be obtained by using 500 bp (185). 
Universal primers complementary to the conserved regions permit the amplification of 
the gene from all bacterial species, and the resulting amplicon contains a unique 
sequence. There are commercially available kits for research-use-only sequencing of 
16S rRNA (MicroSeq; ThermoFisher Scientific, Waltham, MA), but most clinical labora-
tories use laboratory-developed protocols. Notably, some mycobacteria are indistin-
guishable by 16S rRNA gene sequencing, including members of the M. tuberculosis 
complex, the M. avium subspecies, M. chelonae and M. abscessus, M. kansasii and 
Mycobacterium gastri, M. marinum and M. ulcerans, M. senegalense and M. conception-
ense, M. farcinogenes and M. houstonense, M. murale and M. tokaiense, M. mucogenicum 
and M. phocaicum, M. malmoense and M. szulgai, M. peregrinum and M. septicum, and 
M. porcinum and M. fortuitum. Further differentiation may be required for some of these 
groups for epidemiological or clinical reasons. Most of these organisms can be differ-
entiated by sequencing of other genes, such as the internal transcribed spacer (ITS), 
rpoB, secA, or  hsp65 (186–188). To separate the species within the M. tuberculosis 
complex, gyrB sequencing or deletion analysis is needed (113, 189, 190).
Sequence results are more robust than the results of conventional biochemical 
methods because they are less subjective given a comprehensive and accurate data-
base for comparison. Analysis of the sequence data involves evaluating the quality of 
the sequence obtained and subsequent comparison of the sequence with known 
sequences through public and/or commercial databases such as NCBI GenBank, Micro-
Seq, the Integrated Database Network System (SmartGene, Raleigh, NC), or RipSeq 
(Isentio, Sunnyvale, CA). Since there are no FDA-cleared databases, users must carefully 
verify the performance of databases used in laboratory-developed protocols, as the 
quality of the databases varies. Based on CLSI recommendations, 100% identity is 
needed to identify an isolate to the species level. Identifications with 99.0 to 99.9%
confidence should be reported as “Mycobacterium, most closely related to (species).” 
Isolates with 95.0 to 98.9% identity should be reported only to the genus level or with 
the comment “Unable to definitely identify by 16S rRNA gene sequencing, most closely 
related to Mycobacterium spp.” (191). When possible, additional language should be 
included in the report regarding the M. tuberculosis complex. For example, if the M. 
tuberculosis complex can be ruled out, one should consider reporting the organism as 
“Mycobacterium spp. not M. tuberculosis complex.”
MALDI-TOF MS
MALDI-TOF MS is being used with increasing frequency to identify mycobacterial 
isolates. MALDI-TOF MS detects the abundance of proteins with specific mass-to-charge 
ratios, which is displayed as a spectrum. The spectral data are then compared to a 
database to determine the likely identity of the organism. There are currently two 
commercially available MALDI-TOF MS systems in the United States, the MALDI Biotyper 
(Bruker Daltonics, Billerica, MA) and the Vitek MS system (bioMérieux, Durham, NC). The 
Vitek MS system has an FDA-cleared database, which includes mycobacteria (192). 
Laboratories using the MALDI Biotyper must build their own databases or rely on 
research-use-only databases for their laboratory-developed protocols (193). Like 16S 
rRNA gene sequencing, the accuracy of MALDI-TOF MS is dependent on both the 
robustness of the database and the quality of the spectra obtained. Obtaining quality
spectra can be difficult with mycobacteria due to their complex cell walls. Therefore, 
whole-cell preparations (i.e., applying a colony directly on a target plate) do not work 
for mycobacteria. A preextraction step must occur, usually involving bead beating or 
vortexing in ethanol, formic acid, and acetonitrile; the extracted proteins are then 
spotted onto the plate (194, 195). Importantly, the extraction procedure should be 
performed in a BSL-3 laboratory (or a BSL-2 laboratory using BSL-3 practices) and 
verified for its ability to effectively kill M. tuberculosis complex bacteria prior to moving 
the target plate to the mass spectrometer.
Several studies have demonstrated the ability of MALDI-TOF MS to identify clinically 
relevant rapidly growing mycobacteria, including M. immunogenum, M. chelonae, and 
M. abscessus (194–198). However, the subspecies of M. abscessus cannot be differenti-
ated by MALDI-TOF MS. Slowly growing mycobacteria, including the MAC and the M. 
tuberculosis complex, have also been evaluated by MALDI-TOF MS. The M. tuberculosis 
complex, the members of which cannot be easily differentiated, can reliably be 
identified by MALDI-TOF MS, as can M. avium, M. intracellulare, M. kansasii, M. xenopi, 
M. marinum, and several other clinically relevant species (194–198). Of note, studies 
investigating slowly growing mycobacteria often use 14 to 21 days of growth to 
accumulate enough biomass for MALDI-TOF MS identification (194, 197). Unfortunately, 
this delay increases the time to reporting compared to what can be achieved with 
sequencing. Furthermore, the MALDI-TOF MS identification of mycobacteria has been 
studied mainly using isolates on solid media. Identification directly from broth media, 
such as BD MGIT or VersaTREK Myco broth, looks promising, but more studies are 
needed to determine the appropriate scores to use for the acceptability of species-level 
identifications (193, 196, 197). MALDI-TOF MS identification is relatively inexpensive to 
perform after the initial instrument expense (199). It takes about 90 min to obtain a 
MALDI-TOF MS result, compared to 1.5 days for sequence-based identifications.
HPLC
HPLC was first proposed for the identification of mycobacteria by the CDC in 1985 
and was offered as a standard test at the CDC Mycobacteriology Reference Laboratory 
in 1990 (200, 201). HPLC can identify rapidly growing mycobacteria into groups or 
complexes but is not specific enough to identify most species. HPLC has been replaced 
in most laboratories by molecular methods (e.g., rpoB gene sequencing and MALDI-
TOF) for more accurate species identification.
A commercial HPLC system, the Sherlock Mycobacteria Identification System 
(MYCO-LS) (MIDI Inc., Newark, DE), is an FDA-cleared HPLC method for the identification 
of mycobacteria. MYCO-LS identifies 25 species of mycobacteria by the analysis of 
mycolic acids. Like the CDC HPLC method, mycolic acids are extracted from unknown 
mycobacteria, and the HPLC mycolic acid profile is then compared to a library of 
reference strain profiles. The mycobacteria may be identified to the species or to the 
species-complex group level. Several studies have evaluated MYCO-LS and found that 
it is a rapid and accurate alternative method for mycobacterial species identification; 
however, it has a limited library of mycobacteria (202, 203).
Conventional Biochemicals
Identification of mycobacteria has traditionally relied on phenotypic characteristics 
such as the growth rate, colony morphology and pigmentation, optimal growth 
temperature, and reactions in a battery of biochemical tests. Many of these tests 
require growth on solid media, are poorly reproducible, and can take several weeks of 
incubation before species-level identification can be done (204). In addition, variability 
in phenotypic characteristics can be seen within strains of a species. With the devel-
opment of molecular methods for the identification of mycobacteria, there are close to 
200 recognized Mycobacterium species (6). Many of these new species have not been 
characterized biochemically and cannot be reliably identified by using biochemical 
methods.
It is now recommended that laboratories not rely on biochemical methods for the 
identification of Mycobacterium species (132, 205). Rapid molecular methods such as 
commercial DNA probes; sequencing of certain genes such as 16S rRNA, rpoB, hsp65, 
and other genes; as well as MALDI-TOF MS can now provide more accurate and rapid 
mycobacterial identification. If these capabilities are not available locally, isolates 
should be referred to a reference laboratory (205).
Lateral Flow Assays
Immunochromatography-based lateral flow assays using monoclonal antibody 
against the MPB64 protein (Rv1980c or RD2) secreted by the M. tuberculosis complex 
are reported to be reliable, rapid, and simple tools to identify the M. tuberculosis 
complex and differentiate its members from NTM in growth-positive solid or liquid 
cultures (206–209). At present, three commercial tests are available for routine clinical 
diagnostic use, the SD Bioline Ag MPT64 Rapid assay (Standard Diagnostics, Kyonggi-
do, South Korea) (CE marked), the Capilia TB-Neo assay (Tauns, Numazu, Japan) (CE 
marked), and the MGIT TBc Identification test (Becton-Dickinson Instrument Systems, 
Sparks, MD, USA) (CE marked).
The Capilia TB-Neo assay is a second-generation test that eliminated previous 
cross-reactions with certain NTM and nonmycobacterial bacteria to improve specificity 
(210). Due to mutations (most commonly due to a 63-bp deletion at position 196) in the 
gene encoding MPB64, the test gave false-negative results for some M. bovis BCG and, 
more recently, M. africanum variants (211–213). According to a recent meta-analysis, 
the overall sensitivity, specificity, and positive and negative predictive values of the 
Capilia TB assay (first generation) for clinical specimens were 98.8%, 99.1%, 99.4%, and 
98.2%, respectively; those of SD Bioline were 97.0%, 100%, 100%, and 87.2%, respec-
tively; and those of MGIT TBc were 97.9%, 99.5%, 99.7%, and 96.8%, respectively (214).
Completion of the assay requires a BSL-3 laboratory and manipulation in a BSC. 
However, SD Bioline was noninferior regarding performance characteristics when per-
formed on heat-inactivated (1 h at 80°C) growth-positive MGIT broth, which offers the 
possibility of performing the test on these inactivated samples outside a BSC (Loga-
nathan Prabakaran, FIND India Office, personal communication).
ANTIMICROBIAL SUSCEPTIBILITY TESTING
The determination of antimicrobial resistance in mycobacteria is important for 
patient treatment, and with the M. tuberculosis complex, it is essential not just for 
individual patient treatment but also for TB control. AST information guides treatment, 
which is especially vital with the emergence of drug-resistant strains and for estimating 
the prevalence of drug resistance in a community. Phenotypic, culture-based tech-
niques for AST rely on the isolation of the organism, and although there are some 
molecular methods available, phenotypic testing must still be performed. Nevertheless, 
there are a limited number of methods available and even fewer that are FDA cleared 
for the U.S. market.
This section discusses the available AST methods for M. tuberculosis complex and 
NTM. If AST for the M. tuberculosis complex cannot be performed in-house, the 
specimen and/or isolate should be referred to a laboratory that has the capability to 
perform this testing, such as a local or state public health laboratory. The CDC Division 
of TB Elimination Laboratory Branch and some reference laboratories also provide 
certain reference AST services.
Antimicrobial Susceptibility Testing for the Mycobacterium tuberculosis Complex 
AST for the M. tuberculosis complex should be performed on at least the initial 
isolate from each patient with TB. AST can be repeated after 3 months or earlier, if a 
patient remains culture positive and/or is not responding to treatment (98, 115). If the 
M. tuberculosis complex is isolated from a different specimen source, it may also be 
appropriate to perform AST on an isolate from that different source. Once a culture has 
been confirmed as M. tuberculosis complex, AST should be performed by a growth-
TABLE 12 Critical concentrations for testing M. tuberculosis in solid and liquid mediaa
Drug
Critical concn of drug (g/ml)
LJ mediumb 7H10 agarb 7H11 agarb MGIT960b VersaTREKc
Isoniazidd 0.2 0.2 (1.0) 0.2 (1.0) 0.1 (0.4) 0.1 (0.4)
Rifampin 40.0 1.0 1.0 1.0 1.0
Ethambutol 2.0 5.0 7.5 5.0 5.0
Pyrazinamide 100.0 300.0
Streptomycin 4.0 2.0 2.0 1.0
Amikacin 30.0 4.0 1.0
Kanamycin 30.0 5.0 6.0 2.5
Capreomycin 40.0 4.0 2.5
Ethionamide 40.0 5.0 10.0 5.0
Cycloserine 30.0
PAS 1.0 2.0 8.0 4.0
Ofloxacin 4.0 2.0 2.0 2.0
Levofloxacin 1.0 1.5
Moxifloxacine 0.5/2.0 0.5/2.0
Linezolid 1.0
aLJ, Löwenstein-Jensen; 7H10 agar, Middlebrook 7H10 agar; 7H11 agar, Middlebrook 7H11 agar; PAS, para-
aminosalicylic acid.
bSee reference 221.
cSee reference 343.
dSome laboratories may test an additional higher isoniazid concentration (shown in parentheses) to 
differentiate between low- and high-level isoniazid resistance.
eTwo concentrations are proposed by the WHO. In programs using ofloxacin or levofloxacin and 
moxifloxacin, possible testing is for moxifloxacin only at both concentrations (0.5 and 2.0 g/ml) or test 
ofloxacin or levofloxacin at its appropriate level, and moxifloxacin at the higher concentration (2.0 g/ml). 
In programs using ofloxacin or levofloxacin only, test only these drugs. For programs using only 
moxifloxacin, testing is performed with the higher concentration (2.0 g/ml) of moxifloxacin only.
based method. This method should include, at a minimum, AST for the first-line 
antituberculous drugs RIF, INH (2 concentrations), EMB, and PZA. If RIF resistance or 
resistance to any two of these drugs is detected, testing for susceptibility to additional, 
second-line drugs should be performed.
Phenotypic methods for AST. Most growth-based conventional methods test the 
susceptibility of the microorganism to a critical concentration of the drug. The 
critical concentration (Table 12) represents the lowest concentration of the drug 
that inhibits 95% of wild-type strains of M. tuberculosis that have never been 
exposed to anti-TB drugs and does not inhibit patient strains that are considered 
to be resistant. Essentially, the critical concentration differentiates antimicrobial-
susceptible from antimicrobial-resistant strains and is based on international con-
vention (215, 216). For some drugs, e.g., RIF, the critical concentration is well 
established, but for other drugs, there are fewer data to support a critical concen-
tration, and for certain drugs, it can be difficult to determine low-level resistance. 
Another AST method, broth microdilution, can be used to determine a MIC for each 
drug. The MIC represents the lowest concentration of an antimicrobial, in a series 
of dilutions of a drug, that will inhibit the visible growth of a microorganism (217). 
Cambau et al. (218) utilized MGIT960 instrumentation equipped with TB eXiST 
software to establish quantitative AST for M. tuberculosis and compared the results 
with those of genotypes associated with drug resistance.
AST by growth-based methods should always be performed on a pure M. tubercu-
losis complex culture, as contaminating organisms can affect susceptibility results. 
When AST is performed, the bacteria should be inoculated onto solid media such as 
Middlebrook 7H10 or 7H11 agar as well as blood agar plates to determine colony 
morphology and to check for purity. In cases where cultures are mixed, agar plates are 
useful for identifying and separating M. tuberculosis complex and NTM because organ-
isms can be picked and reisolated for purity.
The indirect AP method is considered the reference standard method for phenotypic 
AST of M. tuberculosis complex isolates. However, it is a labor-intensive method, with 
the calculation of resistance by performing colony counts, which requires skilled staff.
In addition, there is a longer turnaround time, up to 3 weeks, than those of broth-based 
methods. The indirect AP method is not commonly used for first-line drugs in diag-
nostic laboratories for these reasons, and commercial broth-based methods are favored 
in the clinical laboratory setting and recommended for use by the CLSI. The following 
section details common commercial broth-based methods. For those methods that use 
critical concentrations, they are based on comparison to indirect AP and are defined as 
equivalent critical concentrations (219). To provide susceptibility data to health care 
providers earlier, some laboratories perform a direct AP method on the processed 
AFB-positive sediment once the AFB are identified as belonging to the M. tuberculosis 
complex.
The Bactec MGIT 960 method (Becton Dickinson, Sparks, MD) is used for the growth 
and detection of mycobacteria as well as AST. For AST, MGIT tubes containing the 
critical concentrations of drugs (Table 12) can be inoculated from solid or liquid M. 
tuberculosis complex isolates. For inoculation procedures, the manufacturer’s instruc-
tions must be followed. A categorical susceptible or resistant result is provided. Some 
laboratories may use EpiCenter software in order to monitor growth dynamics (220). 
This method is FDA cleared for RIF, INH, EMB, PZA, and streptomycin. Other drugs may 
be tested as a laboratory-developed test (221). If there are any other deviations from 
the manufacturer’s instructions, the test must be verified in-house as a laboratory-
developed test.
The VersaTREK method is an automated system used for the growth and detection 
of mycobacteria as well as AST. Tubes containing critical concentrations of the drugs 
(Table 12) can be inoculated with solid or liquid cultures, according to the manufac-
turer’s instructions. This method is FDA cleared for RIF, INH, EMB, and PZA, and other 
drugs may be tested as laboratory-developed tests. A categorical susceptible or resis-
tant result is provided.
The TREK Sensititre method (ThermoFisher Scientific, Oakwood Hills, OH) is a 
semiautomated research-use-only broth microdilution method for susceptibility testing 
of mycobacteria in a microtiter plate format. This method uses a 96-well plate that is 
inoculated with a series of dilutions of first- and second-line drugs (a total of 12 drugs 
are provided, each with a minimum of 7 dilutions on the standard plate). Microtiter 
plates can be inoculated from solid or liquid cultures. The plate is incubated and read 
at intervals for visible growth and determination of the MIC, according to the manu-
facturer’s instructions, at 7, 10, 14, and 21 days. The standard plate tests for resistance 
to the following drugs: RIF, INH, EMB, streptomycin, rifabutin, ethionamide, amikacin, 
kanamycin, ofloxacin, moxifloxacin, cycloserine, and para-aminosalicylic acid. This test 
determines MIC values, but there are no guidelines for the interpretation of suscepti-
bility or resistance results; however, this information, when considered in comparison 
with the established critical concentration of a drug and its achievable serum concen-
tration in healthy individuals, can be a valuable tool to assess the degree of resistance 
and, in turn, guide the adjustment of treatment.
If AST for the M. tuberculosis complex is not available, specimens or isolates should 
be sent to a reference laboratory for testing. The capabilities of public health labora-
tories vary from state to state, but many states have laboratories that are able to 
provide AST for the M. tuberculosis complex or are able to refer specimens to the public 
health AST reference laboratory (California Department of Public Health Laboratory) or 
to the CDC (222). If testing is performed in-house, it is important to have a robust 
quality assurance program, which includes elements such as quality control, proficiency 
testing and performance monitoring (as discussed in Quality Assurance, below), and 
appropriate biosafety practices (as discussed in Biosafety, above). For AST, quality 
control should include the use of a fully susceptible isolate (e.g., M. tuberculosis strain 
H37Rv). With caution, a drug-resistant strain may be included; however, a resistant 
strain should not be resistant to more than two drugs, as this poses safety concerns 
according to the CLSI (219). Quality control organisms should be included whenever 
there is a new lot or shipment, weekly, or every run (depending on the manufacturer’s 
instructions or according to a laboratory’s IQCP). Drug resistance rates should be
TABLE 13 Commonly used phenotypic methods for AST of the M. tuberculosis complex in the United States
Growth-based method Format Comments
Indirect agar proportion method Critical concn; solid media (Middlebrook 7H10
or 7H11 agar); turnaround time of 1 mo
from setup date
Criterion “gold standard”; complex method; pyrazinamide
testing not available; long turnaround time; laboratory-
developed test; not commercially available
Bactec MGIT320 or MGIT960
mycobacterial detection system
(Becton-Dickinson)
Critical concn; liquid media (MGIT);
turnaround time of 4–13 days from setup
date
Reported issues with ethambutol critical concn and false
pyrazinamide resistancea; FDA cleared for first-line
drugs
VersaTREK (ThermoFisher Scientific) Critical concn; growth matrix liquid/sponge;
turnaround time of 4–13 days from setup
date
FDA cleared for first-line drugs
Sensititre (ThermoFisher Scientific) MIC; liquid media; turnaround time of 14–21
days from setup date
PZA testing not available; no MIC interpretive criteria;
research-use-only test
aSee references 344 and 345.
monitored to detect unusual increases or decreases in the rates, which may indicate 
problems with AST. Proficiency testing should be performed for quality assurance and 
is available for first-line drugs through the CAP, the American Proficiency Institute (API), 
and Accutest (summarized in Table 3). The CDC also provides a voluntary Model 
Performance Evaluation Program for the evaluation of test performance that includes 
strains with various resistance patterns. (https://www.cdc.gov/tb/topic/laboratory/
mpep/).
A summary of the most commonly used growth-based methods in the United States 
is provided in Table 13.
Molecular AST methods. Molecular methods detect mutations in genes associated 
with resistance to anti-TB drugs. These methods are rapid and specific, but phenotypic 
AST must still be performed, as genotypic resistance may not always translate to 
phenotypic resistance. If they are available, molecular AST methods should be used in 
an AST algorithm since they can provide timely information to the clinician about drug 
resistance and may be superior to broth-based AST, e.g., for PZA (223, 224). If molecular 
methods for the detection of resistance are not performed, the specimen/isolate may 
be referred to a laboratory that has the capability to perform this testing, such as a 
reference laboratory or a local or state public health laboratory. The CDC provides 
certain AST services, including the MDDR program (http://www.cdc.gov/tb/topic/
laboratory/guide.htm), which provides molecular testing for resistance to a range of 
first- and second-line drugs (112).
The Xpert assay is an FDA-cleared, rapid, real-time PCR test that simultaneously 
detects the presence of the M. tuberculosis complex and mutations in the RRDR of rpoB. 
RIF resistance detected by Xpert requires confirmation by additional AST methods (156)
(see “Detection of Antimicrobial Resistance,” above, for more information on the 
molecular detection of drug resistance and Table 10 for interpretation and reporting of 
Xpert results). Since many clinical laboratories may have an Xpert instrument for other 
tests, the implementation of the moderately complex Xpert test makes screening for 
RIF resistance more widely available. Note that testing of specimen types other than 
sputum must be carefully verified as a laboratory-developed test for off-label usage 
(225).
The GenoType MTBDRplus Version 2 assay is a PCR-based line probe assay for the 
detection of the M. tuberculosis complex, mutations in the rpoB gene associated with 
resistance to RIF, and mutations in the inhA and katG genes associated with resistance 
to INH. This rapid test can be performed directly on the specimen or from culture 
isolates (184, 226). An additional assay, MTBDRsl Version 2 (Hain Lifescience, Nehren, 
Germany), is also available, which detects mutations in the gyrA, gyrB, rrs, and eis genes 
associated with resistance to FQ and aminoglycosides-cyclic peptides (227). Nipro 
Corporation (Japan) has developed a line probe assay (Nipro NTMMDRTB) that is like 
that of Hain Lifescience. This assay allows the detection of RIF and INH resistance-
conferring mutations, the identification of the M. tuberculosis complex, and the iden-
tification of some common NTM, including M. avium, M. intracellulare, and M. kansasii
TABLE 14 Summary of some molecular methods for M. tuberculosis complex AST
Molecular method Format Description
Xpert MTB/RIF (Cepheid) Real-time PCR; detects mutations in the rpoB gene;
turnaround time of 2 h
FDA cleared; rifampin resistance only; ease of use
GenoType MTBDRplus and MTBDRsl
(Hain Lifescience)
Line probe assay; MTBDRplus detects mutations in
the rpoB, inhA, and katG genes; MTBDRsl detects
mutations in the gyrA, gyrB, rrs, and eis genes;
turnaround time of 6 h
Research use only (U.S.); rifampin and isoniazid
on the same line probe assay; additional assay
for fluoroquinolones and aminoglycosides
(amikacin or kanamycin)-cyclic peptides
(capreomycin); interpretation of test results
and result reporting require laboratory
expertise; type of mutation is important and
may direct additional testing necessary for
patient treatment
Sequencing (Sanger sequencing
and pyrosequencing)
DNA sequencing; detects mutations in target
genes; turnaround time of 24 h
Laboratory-developed test; able to detect
mutations in any targeted genes;
pyrosequencing for shorter sequences only
(e.g., not pncA); interpretation of test results
and result reporting require laboratory
expertise; type of mutation is important and
may direct additional testing necessary for
patient treatment
(228). These tests are research-use-only tests in the United States but are CE marked for 
use in Europe. Other CE-marked assays include the Autoimmun Diagnostika GmbH TB 
Isoniazid, Rifampin; TB Aminoglycoside; and TB Fluoroquinolone, Ethambutol kits (229).
Sequencing methods can be used to target a variety of genes to determine 
mutations associated with resistance. Sanger sequencing can be used for any DNA 
sequencing, e.g., the pncA gene to detect mutations associated with PZA resistance. 
Since pyrosequencing methods are used for shorter DNA fragments, this method is not 
useful for the pncA gene, where sequencing of the 670-bp amplicon is required. These 
sequencing methods are laboratory-developed tests but can still play an important role 
in AST for the M. tuberculosis complex (230, 231). An example of when such sequencing 
may be necessary is when performing the Sensititre MIC method for phenotypic AST. 
This method does not allow testing with PZA since it does not have the acidic 
conditions required for the growth-based testing of this drug. Sequencing and identi-
fying mutations in the pncA gene can provide information on the potential for PZA 
resistance. However, not all PZA resistance is determined by the pncA gene and not all 
mutations in the pncA gene are relevant, and additional phenotypic testing may still be 
needed (223). Next-generation sequencing technologies are advancing at a rapid pace 
and are beginning to play roles in identification, AST, and more (223, 232, 233).
Quality assurance considerations for molecular methods include proficiency testing 
and performance evaluations (234), especially the potential for false-positive results for 
tuberculosis in low-prevalence populations like that of the United States; similarly, false 
RIF resistance has been reported (235, 236). The only CMS-approved proficiency testing 
program available exclusively for M. tuberculosis PCR and molecular detection of RIF 
resistance is available through the Wisconsin State Laboratory of Hygiene proficiency 
testing service. A summary of some of the molecular methods is provided in Table 14.
Antimicrobial Susceptibility Testing for Nontuberculous Mycobacteria
The presently accepted recommendations and guidelines for in vitro AST of clinically 
significant NTM isolates are summarized in recommendations of the ATS and IDSA from 
2007 (52) and in guidelines of the CLSI from 2011 (219). A review by Brown-Elliott and 
colleagues (54) provides additional important recommendations and updates.
The role and relevance of in vitro AST of NTM to guide the treatment and clinical 
management of patients with NTM disease are under continuous debate. The basis of 
this debate is that, in contrast to the M. tuberculosis complex, the clinical response to 
antimycobacterial drugs or antibiotics has been shown to correlate with only some 
compounds and in only some NTM (e.g., the MAC and macrolides and amikacin, M.
kansasii and RIF, M. marinum, and M. fortuitum), whereas similar correlations for several 
other clinically significant NTM (e.g., M. abscessus) were not or could not be established. 
On the other hand, most clinically significant NTM isolates already show intrinsic 
resistance or high in vitro breakpoints for several antibiotics upon first isolation (54). 
Therefore, AST on NTM seems to be logical and necessary to accumulate data on in vitro 
AST patterns for NTM. However, it is important to keep in mind that performing AST on 
clinically nonsignificant NTM isolates is a waste of time and resources, and results may 
be misleading for patient management. Because most NTM are ubiquitous in soil, 
water, and other environmental sources, determination of the clinical significance of an 
isolate is warranted before initiating any AST. Additionally, AST results for NTM can be 
method and species dependent.
Rapidly growing NTM. The gold-standard method for AST of rapidly growing NTM 
is a broth microdilution assay; a commercial research-use-only product is the TREK 
Sensititre MIC plate. At this time, there are no FDA-cleared platforms for NTM AST. AST 
of rapidly growing NTM should have rigorous quality control using CLSI-recommended 
reference strains to ensure not only quality testing but also reproducibility of MICs 
within the recommended and acceptable ranges for antimicrobials tested. MIC results 
for imipenem, meropenem, and tetracycline may be invalid after more than 5 days 
of incubation because of stability-related problems with these drugs (54). Isolates 
that are susceptible to clarithromycin should be further incubated for 14 days to 
rule out inducible macrolide resistance, which is a common phenomenon due to 
the presence of an rRNA methylase erm gene present in most clinically significant 
rapidly growing NTM.
To decrease the turnaround time and save resources on prolonged incubation, 
routine DNA sequencing of particular erm genes, such as erm(41) in M. abscessus, may 
facilitate both the rapid detection of macrolide-inducible resistance and subspecies 
identification of M. abscessus isolates (82, 237). Hain GenoType NTM-DR Ver 1.0 can 
detect macrolide resistance [erm(41)] and subspecies of M. abscessus within 5 h and is 
CE marked in Europe (238). Breakpoints have not been established by the CLSI for 
additional methods, such as agar disk diffusion and Etest (bioMérieux, Durham, NC), or 
have shown problems with reproducibility (54), and therefore, these methods are not 
recommended for AST of rapidly growing NTM.
Slowly growing NTM. For slowly growing NTM, the CLSI-recommended method for 
AST is a broth-based assay, except for M. haemophilum, for which the recommended 
method is an agar disk elution that requires more prolonged incubation (54, 219). Hain 
GenoType NTM-DR Ver 1.0 can detect resistance to macrolides and aminoglycosides 
and identify MAC isolates to the species level and is CE marked in Europe. Recommen-
dations of the ATS/IDSA (52) and the CLSI (219) for AST of slowly growing NTM include 
the following. Clarithromycin susceptibility testing is recommended for new and 
previously untreated MAC isolates. No other drugs are recommended for AST of new 
and previously untreated MAC isolates. There is no recognized value for testing of MAC 
isolates against first-line antituberculosis agents. Clarithromycin susceptibility testing 
should be performed for MAC isolates from patients who fail macrolide therapy or 
prophylaxis. Previously untreated M. kansasii isolates should be tested against rifampin 
only. Isolates of M. kansasii that show susceptibility to rifampin will also be susceptible 
to rifabutin. M. kansasii isolates that are resistant to rifampin should be tested against 
a panel of secondary agents, including rifabutin, ethambutol, isoniazid, clarithromycin, 
fluoroquinolone, amikacin, sulfonamides, and linezolid. M. marinum isolates do not 
require susceptibility testing unless the patient fails treatment after several months. 
There are no current recommendations for one specific method of in vitro AST for 
fastidious NTM species (e.g., M. haemophilum) and some less commonly isolated NTM 
species. Verification and quality control must be in place for AST of all species of NTM.
Considerations about Antimicrobial Susceptibility Testing for Mycobacteria
Many laboratories do not have the capability or have a limited capability to perform 
AST and, as discussed in this section, may need to refer specimens and isolates to other
laboratories. There are a few considerations when referring specimens and/or isolates. 
First, submitting and referral laboratories should be familiar with shipping guidelines 
for infectious substances. Second, laboratories should consider the techniques that are 
used at the referral laboratory for AST, the drugs that are tested, the turnaround time, 
and reporting mechanisms. Third, laboratories should consider referring specimens for 
molecular M. tuberculosis complex AST, especially if resistance is suspected. Even if a 
laboratory has culture capabilities, specialized laboratories and the CDC can perform 
molecular AST on the specimen and provide susceptibility data to health care providers 
earlier than with growth-based AST. Laboratories should also consider referring isolates 
for M. tuberculosis complex AST if they do not have the capability in-house. Ideally, 
mycobacteria that have been identified can be referred by using primary liquid cultures 
(rather than waiting for solid medium, although this can also be sent). Finally, AST for 
slowly and rapidly growing NTM is offered in only a few reference or public health 
laboratories, and these laboratories may test additional compounds on a research-use-
only basis.
A common challenge with the M. tuberculosis complex is discordant results, espe-
cially when testing is performed by multiple, complex techniques and at more than one 
laboratory. There are several reasons for discordant results, including but not limited to 
the following: the culture is not pure; the isolate itself may consist of subpopulations; 
comparison of results from different methods, e.g., phenotypic versus genotypic, or 
testing performed on different media (with different inocula and/or different critical 
concentrations), is difficult; methods are not standardized; the result is an MIC, and the 
result may be close to the critical concentration; and laboratory error with mislabeling 
or contamination is possible (115). Van Deun et al. (239) described discordant antimi-
crobial susceptibility results between growth-based and molecular testing during a 
proficiency testing event. In that study, it was concluded that low-level but probably 
clinically relevant RIF resistance linked to specific rpoB mutations can be missed by 
growth-based methods. A guide was reported by Hofmann-Thiel et al. (240) providing 
suggestions for investigating discordant molecular test results, including results of 
Xpert and line probe assays and growth-based assays for rifampin resistance.
QUALITY ASSURANCE
High-quality clinical laboratory testing is an integral part of providing quality health 
care. Quality assurance programs and indicators ensure that laboratories monitor and 
improve their clinical testing services through ongoing analysis and assessment. This 
section discusses several quality assurance features that laboratories should consider 
integrating into their quality management program in the mycobacteriology labora-
tory. Within the quality plan, several parameters should be addressed, including general 
laboratory systems and preanalytical, analytical, and postanalytical phases of testing.
CLSI document QMS12-A provides laboratories general suggestions on developing 
key quality indicators in the laboratory setting (241). A clear process that addresses the 
development and use of quality indicators is effectively described in this document, 
along with other meaningful tools related to process improvement.
Specimen Collection
A robust quality assurance program begins with adequate specimen collection. It is 
incumbent on the laboratory to appropriately communicate specimen requirements to 
the health care provider to ensure the best-quality outcome for the patient. This 
communication should be regular in some capacity, since providers change and 
knowledge can be forgotten. Provider instructions are a crucial component to ensure 
that adequate specimens are collected, labeled, and transported appropriately for 
processing. Communication with the provider as to which specimens will be rejected 
is important and should be reinforced on an ongoing basis. The optimal specimen 
collection volume for sputum is 5 to 10 ml (75). It is known that the volume of sputum 
can directly impact the ability of the laboratory to recover and isolate mycobacteria 
from a specimen and that submission of a specimen of 3 ml may negatively impact
organism recovery. If specimens that are 5 ml are routinely submitted, there should 
be a mechanism in the laboratory to monitor appropriate specimen collection (see 
“Acceptable Specimens and Rejection Criteria,” above), and the laboratory should 
consider a quality monitor to assess specimen volume and have a mechanism for 
provider feedback if specimen requirements are not being followed (103). It is recom-
mended that the provider be notified of unsatisfactory specimens as soon as possible 
or within 24 h. Instructions to the provider should clearly state that sputum from deep 
in the respiratory tract is the optimal specimen, as opposed to saliva. Monitoring the 
number of specimens per patient can also be part of a robust quality assurance 
program. In larger systems, tracking the numbers of specimens per patient could be 
onerous unless an electronic mechanism to do so is readily available.
Critical to patient care and management from an infection control perspective is the 
laboratory’s role in the timely processing and reading of AFB smears. The laboratory 
must process specimens as soon as possible after collection and/or arrival in the 
laboratory and provide AFB smear results within 24 h of receipt of the specimen in the 
laboratory (103, 242). Specimen delivery can also be broken down into many segments 
to monitor how effectively specimens are being transported to the laboratory for 
processing, especially if the laboratory is in a remote location compared to either the 
hospital or outpatient facilities. The faster a result is provided to the health care 
provider, the sooner the patient can be appropriately treated, which will augment 
patient care, prevent the unnecessary spread of infection to others, and/or allow the 
patient to be released from isolation sooner (103, 158).
Another quality assurance indicator in the mycobacteriology laboratory is providing 
appropriate feedback to the health care provider. This not only will enhance quality and 
patient care but also can positively impact the laboratory so that time is not wasted 
processing inappropriately submitted specimens (243). Since many health care institu-
tions have electronic medical records, direct feedback about specimen rejection via the 
hospital information system can be a rapid way to educate the provider.
Specimen Processing and Decontamination
Specimen management is very important across all clinical laboratory disciplines. 
Within the mycobacteriology laboratory, it is generally accepted that to maintain 
adequate proficiency for culturing specimens for AFB, a minimum of 20 specimens 
should be processed and cultured per week (103). If these numbers cannot be met, 
laboratories should consider referring specimens to a reference laboratory for testing.
For those laboratories that process and culture AFB specimens, cross-contamination 
with the M. tuberculosis complex is one event that can have serious consequences for 
the patient. After an extensive review performed in 2000, it was determined that the 
median false-positive rate due to cross-contamination in the mycobacteriology labo-
ratory was approximately 3.1% (244). A cross-contamination event not only can result 
in a patient being treated with an inappropriate course of antibiotics but also can mask 
the true underlying condition or disease of the patient (245, 246). Laboratory practices 
should be in place not only to mitigate cross-contamination but also to uncover a 
contamination event if it occurs. The integrity of the laboratory rests on mitigating 
these events. The laboratory understanding of a root-cause analysis can be crucial to 
investigations related to contamination events (132).
There are several steps/processes that can be integrated into the specimen-
processing procedure that will reduce errors associated with cross-contamination. 
These steps/processes can include, but are not limited to, the following: (i) supple-
menting broth cultures with the appropriate antibiotic cocktail prior to inoculating the 
sample aliquot; (ii) performing all work on towels soaked with an appropriate disinfec-
tant to minimize droplets from the specimen contaminating surfaces or other materials;
(iii) opening and processing one patient sample at a time within the BSC; (iv) using 
“single-use” reagents such as buffers that are part of the decontamination procedure;
(v) if using Pasteur or serological pipettes, using only pipettes that have cotton plugs, 
which can reduce contamination of equipment associated with pipetting steps; (vi)
performing follow-up on specimens from first-time-positive AFB patients that are 
processed in the same batch as specimens of other known positive patients; and (vii) 
as recommended by the WHO Global Laboratory Initiative, including one negative-
control specimen and one positive-control specimen weekly with a batch of clinical 
specimens (134). However, the inclusion of a positive control in the processing of 
patient specimens is discouraged due to the risk of cross-contamination (1). To resolve 
whether a cross-contamination event has occurred, laboratories can send out the 
isolates from the single-positive patient and the sentinel (possible source specimen 
from a known positive patient) for genotyping. Laboratories can refer these isolates to 
their state or local public health laboratory, which will forward the isolates to a 
CDC-contracted laboratory for genotyping. This definitive approach can truly make a 
difference in patient management and improve the quality of testing in the laboratory. 
An extensive list of measures related to specimen processing and decontamination can 
be found in the 2013 Association for Public Health Laboratories document Mycobac-
terium tuberculosis: Assessing Your Laboratory (103).
Culture Growth
There are several indicators to assess the efficiency of the decontamination and 
digestion procedures, since these steps ultimately affect organism recovery. Contami-
nation of media for culture growth should be monitored within the mycobacteriology 
laboratory. Some contamination of culture medium is expected, but a general approx-
imation is that contamination rates are 2 to 5% for solid media and 7 to 8% for liquid 
media containing antimicrobials (140, 247). There is a balance between mild decon-
tamination, which could result in the overgrowth of non-AFB bacteria and interfere 
with the isolation of the true pathogen, and, conversely, harsh decontamination, which 
can lead to false-negative AFB cultures. Monitoring the contamination rate assists in 
ensuring that digestion and decontamination procedures are adjusted appropriately 
(75). If a contamination rate of 5 to 8% is observed, monitoring the time of transport 
of the specimen to the laboratory may be prudent, as delays in specimen submission 
may be occurring. The longer it takes to transport the specimen to the laboratory, the 
more time the normal flora has to multiply and overgrow AFB. Of note, if only a few 
colonies of non-AFB bacteria are contaminating an agar plate or slant, this should not 
be counted as contamination or overgrowth if the ability to isolate the pathogen is not 
impeded. Solid medium that is completely overgrown or liquefied, thereby making the 
isolation of AFB impossible or severely compromised, is considered contaminated. It is 
also important to monitor specimens submitted from CF patients, which warrant a 
different decontamination procedure (75). See the section Work-Up of Specimens for 
these procedures.
Tracking results for a defined patient population can be a very useful quality 
monitor (248), since an increase in the AFB positivity rate can alert the laboratory of a 
potential outbreak or pseudo-outbreak within the health care institution. However, if 
the positivity rate decreases compared to anticipated percentages, this might mean 
that the decontamination procedure is too stringent, resulting in false-negative cul-
tures. All these quality monitors are important for assessing the robustness of the 
processes and procedures in the mycobacteriology laboratory (103).
For those laboratories performing culture, it is critical that correlation analysis of AFB 
smear and culture results be performed. Excessive numbers of AFB smear-positive/
culture-negative specimens warrant a quality assurance investigation. Findings may 
include contamination with AFB in the test system, such as contaminated broncho-
scopes (51) or contaminated water in general. Mycobacteria can be present in water, 
and autoclaving does not necessarily destroy the acid-fast properties of an organism. 
Too harsh of a decontamination procedure could also be the cause of a higher rate of 
AFB smear-positive, culture-negative specimens (132). The competency of the technol-
ogist reading the AFB smears should also be considered.
Finally, numbers of NAAT-positive, culture-negative specimens should be monitored 
to determine if the decontamination procedure may be too stringent and is killing the
TABLE 15 Suggested quality assurance monitors in the mycobacteriology laboratorya
Area Quality assurance monitorb
Specimen collection Monitor vol of specimens submitted; provide feedback to providers
Monitor no. of specimens per patient; electronic mechanism for larger laboratories would be necessary
Monitor rejected specimens
Turnaround time Monitor specimen delivery turnaround time
Monitor turnaround time for processing specimen
Monitor turnaround time for reporting AFB smear results
Monitor turnaround time for reporting first-line AST results for the M. tuberculosis complex
Cross-contamination Monitor first-time-positive TB patients; send isolates for molecular typing if contamination is suspected
Processing of specimen Monitor robustness of digestion/decontamination procedure by monitoring non-AFB growth in solid
and liquid media
Monitor positivity rate in population
Correlate AFB smear positivity with culture results
Correlate TB NAAT positivity with AFB smear and culture results
aSee reference 248.
bAFB, acid-fast bacilli; TB, tuberculosis; NAAT, nucleic acid amplification test.
mycobacteria in the specimen or if the NAAT result is false positive due to contami-
nation. Wipe testing (sentinel testing) for contamination should be performed period-
ically (249), or at the director’s discretion, in all laboratories performing molecular 
testing to document that the environment is clean. NAAT-negative, culture-positive 
specimens could indicate a contamination event in the processing/culture area of the 
laboratory, so it is important to investigate this as well.
In conclusion, there are several approaches to assessing and monitoring quality 
within the mycobacteriology laboratory. Consultation with other colleagues is also 
prudent when looking for new avenues for continuous quality improvement, in addi-
tion to many of the references in this section. Table 15 lists several quality monitors that 
may be appropriate for laboratories that test specimens for mycobacteria, and bench-
marks can be found in Table 4.
USE OF INTERFERON GAMMA RELEASE ASSAYS FOR DIAGNOSIS OF 
MYCOBACTERIUM TUBERCULOSIS INFECTION
In 2010, the CDC reported updated guidelines (250) for the use of IGRAs as aids in 
diagnosing both LTBI and active TB disease, and in 2014, the American Academy of 
Pediatrics released a technical report entitled Interferon-Gamma Release Assays for 
Diagnosis of Tuberculosis Infection and Disease in Children (251). The primary purpose of 
IGRAs is to identify those who will benefit from LTBI therapy. Prior to 2001, the TST was 
the only immunological test for TB infection approved in the United States. In 2001, the 
Quantifier-TB (QFT) test (Cellestis Limited, Carnegie, Victoria, Australia) was the first 
IGRA approved by the FDA (250). In 2005, the QuantiFERON-TB Gold (QFT-G) test was 
FDA approved (252). Previous guidelines were reported in 2003 for the use of QFT (253) 
and in 2005 for the use of QFT-G (252). Since 2005, two new IGRAs have been FDA 
approved: the QuantiFERON-TB Gold In-Tube (QFT-GIT) test (Qiagen, Germantown, MD 
[formerly Cellestis Limited]) and the T-Spot.TB (T-Spot) test (Oxford Immunotec Limited, 
Abingdon, United Kingdom) (250). These tests may improve specificity and differ from 
previous IGRAs in the antigens used, methods, and interpretive criteria. CDC guidelines 
reported in 2010 address the use of these newer IGRAs (250).
The ATS/IDSA/CDC clinical practice guidelines reported in 2017 (98) recommend 
performing an IGRA instead of a TST for individuals 5 years of age or older who meet 
the following criteria: the individuals are likely to be infected with the M. tuberculosis 
complex, the individuals have a low or intermediate risk of disease progression, it has 
been decided that testing for LTBI is warranted, and the individuals either have a 
history of BCG vaccination or are unlikely to return to have their TST results read. 
Additionally, the guidelines suggest performing an IGRA rather than a TST for all other 
individuals 5 years of age or older who are likely to be infected with the M. tuberculosis 
complex, who have a low or intermediate risk of disease progression, and for whom it 
has been decided that testing for LTBI is warranted. There are insufficient data to
recommend a preference for either a TST or an IGRA as the first-line diagnostic test for 
individuals 5 years of age or older who are likely to be infected with the M. tuberculosis 
complex, who have a high risk of progression to disease, and for whom it has been 
determined that diagnostic testing for LTBI is warranted.
Commercially available IGRAs measure the T cell immune response to antigens that 
are present in M. tuberculosis complex but absent in M. bovis BCG vaccine strains and 
most NTM. It should be noted that although the QFT-GIT and T-Spot tests do not detect 
the M. bovis BCG vaccine strains, both assays detect the M. tuberculosis complex, which 
includes M. bovis. The IGRAs measure IFN- released by sensitized T cells incubated in 
the presence of M. tuberculosis complex-specific antigens. Until the development of the 
IGRAs, the TST was the only method to determine LTBI. The TST has been used for more 
than 100 years and has modest sensitivity and specificity. The IGRAs have specificity, 
especially in BCG-vaccinated populations, and are predicted to be better diagnostic 
tools for LTBI than the TST (250, 254–256).
For the QFT-GIT test, blood is drawn directly into a heparinized tube coated with the 
M. tuberculosis complex-specific antigens ESAT-6, CFP-10, and TB7.7. A second tube 
containing phytohemagglutinin (PHA) acts as a mitogen control that indicates cell 
functionality. A third tube, which contains no antigen or PHA, serves as a nil control. 
Approximately 1 ml of blood is drawn into each tube. The tubes must be incubated 
within 16 h of collection. After incubation for 16 to 24 h at 37°C, the plasma is collected, 
and the concentration of IFN- is determined by using an enzyme-linked immunosor-
bent assay (ELISA). The manufacturer provides calculations and criteria for determining 
a positive result. The test detects infections caused by the M. tuberculosis complex, 
which includes M. tuberculosis, M. bovis, and M. africanum. Specimens from patients 
infected with M. kansasii, M. szulgai, and M. marinum may respond in the assay, as these 
organisms have the genes encoding ESAT-6 and CFP-10 (257).
In 2015, the fourth-generation QuantiFERON-TB Gold Plus (QFT-Plus) ELISA was 
released in markets outside the United States. This assay also measures the response to 
the ESAT-6 and CFP-10 peptide antigens, but it is designed to separately measure the 
response of CD8 cytotoxic T lymphocytes and CD4 T helper lymphocytes to the TB 
antigens. The test has two TB antigen tubes: one tube contains ESAT-6 and CFP-10 
peptides that are designed to stimulate responses from CD4 cells, and a second 
tube contains a set of peptides targeted to induce responses from CD8 cells. M. 
tuberculosis-responsive CD8 cells have been found in patients with LTBI and with 
active TB disease and are more frequently found in active TB disease than in LTBI 
(258–260). Studies have found that CD8 cell responses may be associated with recent 
M. tuberculosis complex exposure (261–263). The QFT-Plus CD8 T cell response may 
help distinguish active from latent TB and discriminate between recent and old 
infections; however, this awaits further studies. The sensitivity of QFT-Plus using 
culture-confirmed M. tuberculosis complex cases as a surrogate for LTBI is 95.3%
according to the package insert (264). The specificity in persons with no known risk 
factors for TB is 97.6% (264).
The T-Spot assay was FDA approved in July 2008. Depending on the patient’s age, 
2 to 8 ml of blood is drawn into a lithium-heparin tube and processed within 30 h of 
collection if T-Cell Xtend is used or within 8 h if  T-Cell Xtend is not used (265). 
Alternatively, blood may be collected into a mononuclear cell preparation tube and 
processed within 8 h of collection. Density gradient centrifugation is used to separate 
the mononuclear cells. T-Cell Xtend contains antibodies that cross-link granulocytes 
to red blood cells and separate the granulocytes, which may reduce the viability of 
mononuclear cells and reduce their ability to release interferon gamma, from the 
mononuclear cells during centrifugation (265). The cells are counted, and approxi-
mately 250,000 cells are added to microtiter wells that are coated with monoclonal 
antibodies to IFN-. ESAT-6 and CFP-10 antigens are then added to two wells, with a 
third well being used as a nil control and a fourth well containing PHA as a cell 
functionality control. The microtiter plates are incubated for 16 to 20 h at 37°C and then 
washed to remove the cells. A conjugated secondary antibody is then added, which
TABLE 16 Persons at increased risk for M. tuberculosis complex infection or at increased risk for progression from latent tuberculosis
infection to active tuberculosisa
Patient population Description
Persons at increased risk for TB infection Those with close contact with known or suspected active TB cases
Foreign-born persons from areas that have a high incidence of active TB
Residents and employees in congregate settings whose clients are at an increased risk for active TB,
especially if visits are frequent or prolonged
Persons who visit areas with a high prevalence of active TB disease
Health care workers who serve persons who are at an increased risk for active TB
Populations defined locally as having an increased incidence of TB infection or active disease (e.g.,
low-income populations and persons who abuse drugs or alcohol)
Infants, children, and adolescents exposed to adults who are at an increased risk for LTBI or active TB
Persons at increased risk for progression
to active TB
Persons living with HIV
Those who are receiving immunosuppressive therapy (e.g., TNF-b antagonists, systemic
corticosteroids, or immunosuppressive drug therapy following organ transplantation)
Those who were infected with Mycobacterium tuberculosis within the last 2 yr
Those with a history of untreated or inadequately treated active TB, including those with fibrotic
changes on chest radiograph consistent with prior TB
Those with silicosis; diabetes mellitus; chronic renal failure; leukemia; lymphoma; or cancer of the
head, neck, or lung
Those who have had a gastrectomy or jejunoileal bypass
Those who weigh 90% of their ideal body wt
Cigarette smokers and those who abuse drugs or alcohol
Those defined locally as having an increased incidence of active TB, including medically underserved
or low-income populations
Infants and children aged 5 yr who are at an increased risk for a poor outcome (e.g., meningitis,
disseminated disease, or death) if active TB occurs
aAdapted from reference 250.
bTNF-, tumor necrosis factor alpha.
binds to the IFN- secreted by the T cells (and captured by the primary antibody). A 
substrate is then added, which produces spots where IFN- was secreted by the T cells. 
The spots that represent sensitized effector T cells are counted. For the T-Spot.TB assay, 
a positive test result is based on the number of spot-forming units. In the United States, 
the FDA-approved criterion for a positive test result is 8 spots, 4 spots are consid-
ered a negative test result, and 5 to 7 spots are considered a “borderline” result. As for 
all tests, the results should be interpreted in conjunction with results of other diag-
nostic tests and epidemiological information to help determine the M. tuberculosis 
complex infection status of the patient.
The 2010 CDC guidelines state that FDA-approved IGRAs, including QFT-G, QFT-GIT, 
and T-Spot, can be used similarly to the TST for the diagnosis of M. tuberculosis complex 
infection in children and adults (250); this includes persons at an increased risk for M. 
tuberculosis complex infection and those at an increased risk for progression to active 
TB, as listed in Table 16. Individuals in these two categories will likely benefit from 
treatment for LTBI. IGRAs may also be used for surveillance purposes, in contact 
investigations, to screen health care workers and other groups at risk for LTBI, and to 
identify persons who are likely to benefit from treatment. The guidelines issue caution 
in using IGRAs for children 5 years of age. Specificity is expected to be high for 
children, but additional studies are needed to evaluate the performance of IGRAs for 
this population.
The CDC guidelines also state that laboratories should report both the qualitative 
test result interpretation and the quantitative assay values along with the criteria used 
for the test result interpretation (250). Reporting the quantitative value is important, 
especially when interpreting results from serial testing (e.g., health care workers), when 
IFN- levels are close to the cutoff value separating positive and negative results. 
Several studies have shown that in individuals serially tested with QFT-IT, those with 
quantitative values near the cutoff of 0.35 IU/ml are more likely to have variability in 
their qualitative result interpretation, positive or negative, than individuals with quan-
titative results farther from the cutoff value (212–214). Providing this information will 
allow the health care provider to make a better assessment of the IGRA results.
There are both advantages and disadvantages to consider when implementing 
IGRAs. Unlike the TST, IGRA results can be available within 24 h, if performed on-site, 
without the need for a second patient visit. In TB contact investigations, a significant 
number of individuals do not return to have their skin tests read, and results are not 
available to help public health professionals prioritize follow-up (266). In addition, 
errors in the placement and reading of skin tests can result in misinterpretation of the 
results and inappropriate patient management. Disadvantages of IGRAs include the 
need to draw blood, stringent blood collection and mixing requirements, and time 
limitations for initial specimen processing or incubation. The T-Spot Xtend reagent can 
be used to extend the time from collection to sample processing in the laboratory to 
30 h, as noted above. However, this still may not be enough time to transport the 
specimen to a distant reference or public health laboratory. IGRAs are complex assays. 
Compared to the TST, which requires 5 steps to complete, QFT-GIT requires at least 126 
separate steps for one test result (267). The cost of IGRAs is higher than that of the TST, 
but studies have shown that the lower rates of positivity of IGRAs and the advantage 
of a single patient encounter, which provides results for a higher percentage of 
patients, may lead to overall savings to the health care system (268).
IGRAs have the potential to improve the diagnosis and management of TB; however, 
there are still outstanding issues concerning the performance characteristics of the 
assays, interpretation of the results, and limitations of IGRAs that require further 
research. For example, although quantitative results are useful for evaluating the 
likelihood of conversions or reversions when values are close to the assay cutoff value, 
there is no consensus on the interpretation and significance of IGRA conversions and 
reversions at this time. Quantitative IGRA results have not been shown to have 
prognostic value, and it is still not known if IGRAs are better than the TST in predicting 
progression to active TB.
Several factors have been shown to impact the results of IGRAs (206–211, 269–274). 
Preanalytical factors such as the amount of time from blood collection to incubation 
can significantly affect IGRA results (269). Other studies have shown that the time of day 
when blood is drawn can also influence the IGRA result (270). A study by Whitworth et 
al. showed that different incubation times within the parameters of the assay protocols 
can affect the quantitative results and the interpretation of the results of the assays 
(271). Another study showed variability of results related to how the QuantiFERON 
tubes are shaken and the quantity of blood in each tube (275). It is important for 
laboratories to standardize and control the parameters of the assays to optimize 
reproducibility.
Health care workers are at an increased risk of exposure to M. tuberculosis complex 
bacteria and have traditionally been screened for LTBI by using the TST. Two excellent 
systematic reviews have summarized data from the studies that have evaluated the use 
of IGRAs on health care workers (276, 277). Some studies have shown high rates of IGRA 
conversions that are not consistent with the low rates of TB seen in the United States 
and the exposure risks of health care workers (278). In 2016, Gamsky et al. (279) 
reported a study on the use of serial QuantiFERON-TB IGRAs on emergency responders 
in a low-TB-prevalence county in California from 2001 to 2013. Those researchers 
concluded that the QuantiFERON-TB IGRA should not be used for the diagnosis of LTBI 
in low-risk populations because of frequent and irreproducible positive results. Most 
studies have also shown high rates of reversions, which are more likely to be seen 
among those with IFN- values or spot counts near the diagnostic cutoff (278). Some 
health care facilities have established their own cutoffs or have implemented retesting 
strategies to eliminate false-positive conversions (280, 281). A 2015 study by King et al. 
that included over 19,000 health care workers from 19 U.S. hospitals showed positivity 
and conversion rates consistent with known TB risk factors using the T-Spot.TB assay 
(282). Suggestions for the standardization of occupational testing programs have been 
proposed to limit the variability in test results and interpretations (283).
Because of the complexity of IGRAs and the many factors that can impact the results 
of the assays, it is especially important to have a strong quality assurance program in 
place. Key quality assurance monitors should be identified, such as the percentage of 
positive results; the percentage of indeterminate or invalid results; the distribution of 
IGRA values, especially those near the cutoff value; and correlation of positive results 
with the patients’ risk factors for TB infection. Gaur et al. found that the blood volume 
and tube shaking impact IGRA results (275). In many laboratories, IGRAs are performed 
in the serology department and not in the TB laboratory. The personnel performing the 
testing must establish a close relationship with the state TB program, local public health 
programs, infection control programs, employee health programs, and health care 
providers to determine the correlation of IGRA results with clinical presentation, chest 
radiography results, results of other diagnostic tests, and epidemiological risk factors 
for TB of the patients. It is important for the laboratory to educate health care providers 
about the variability and limitations of IGRAs so that the results can be interpreted 
appropriately.
USING A REFERENCE LABORATORY
The need for, and availability of, diagnostic mycobacteriology services has under-
gone substantial changes in the recent past. These changes are due to (i) the overall 
decreased incidence and prevalence of TB over the decades, with a concurrent increase 
in the isolation of NTM; (ii) the fact that mycobacterial infections vary geographically 
and by patient populations; (iii) the fact that many community hospitals and clinics see 
few or no patients with NTM infections; (iv) the centralization of clinical services that 
provide care for patients with mycobacterial infections (e.g., public health clinics); (v) 
the increasing complexity and sophistication of testing required to provide diagnostic 
mycobacteriology services; (vi) the need to closely link clinical and laboratory services 
as part of integrated systems for caring for patients with mycobacterial infections; and 
(vii) the ongoing emphasis on controlling costs in health care. Not surprisingly, many 
clinical laboratories have opted to discontinue offering a full range of diagnostic 
mycobacteriology services, instead referring parts or all of these services to reference 
laboratories.
When To Refer Specimens/Isolates to a Reference Laboratory
Clinical microbiology laboratories are faced with decisions as to which laboratory 
services to offer in-house versus which ones to send to a reference laboratory (103). 
Factors that must be considered include the scope of clinical services provided by the 
hospital or clinics served by each laboratory, test volumes, the technical capacity of the 
laboratory, whether the laboratory is part of a larger health care system or network, and 
the availability of reference laboratory services. For most hospital-based clinical micro-
biology laboratories, providing a full scope of mycobacterial cultures and susceptibility 
testing is neither necessary nor appropriate. However, almost all hospital-based labo-
ratories should offer AFB smears.
A more contemporary decision is whether to offer rapid diagnostic testing by methods 
such as the Xpert assay or a line probe assay such as the GenoType MTBDRplus assay. This 
is a decision not only for laboratories that perform both AFB smears and cultures, where 
rapid assays must be integrated into a traditional testing approach, but also for laboratories 
that may need access to a rapid diagnostic test in urgent situations. The Xpert assay 
recently received an expanded product claim that allows clinicians to remove patients with 
suspected TB from AII based on negative test results (147). Because all rapid assays are more 
sensitive when testing AFB smear-positive specimens, the results of rapid molecular assays 
must be interpreted in conjunction with the results of AFB smears (even when AFB smears 
are not performed on-site). Although the Joint Commission standard for reported AFB 
smear results does not mention this test, it is unlikely that the standard would be 
interpreted differently. Therefore, optimally, Xpert results should be available within 24 h if 
the test is being used as part of a program to remove patients from AII based on laboratory
test results. There is no simple, straightforward algorithm for determining the scope of 
mycobacteriology services to offer in each laboratory.
How To Assess Reference Laboratories
Reference laboratories vary widely in their scope of services, expertise, quality, cost, 
test turnaround time, and use of information technology. Even though selection often 
may be driven by other factors, such as participation in a purchasing consortium, 
important factors in selecting a reference laboratory are the scope of services, expertise, 
and an outstanding track record in quality management systems.
Reference laboratories should provide referring laboratories with complete and 
explicit instructions for specimen storage and transport, including information on 
suitable media and temperatures and the acceptable time limit after which specimens 
are no longer suitable for culture or other testing. Information should be provided for 
both clinical specimens as well as cultures that need further testing, with specific 
instructions for different specimen types as well as any need for special culture 
conditions (e.g., temperature of incubation). Because of the potential for the loss of 
microbial recovery due to mishandling or delays, laboratories should monitor recovery 
rates and any discrepant results carefully as part of a quality assurance program.
The turnaround time should also be monitored as part of the laboratory’s quality 
assurance program. Part of the evaluation and selection of competing reference 
laboratories should be an analysis of their total turnaround time from specimen receipt 
to reporting results to clients. Cost is another obvious factor in selecting reference 
laboratories, but due to the wide variability in contracts and other factors, it often is 
beyond the control of the clinical laboratory director. Moreover, large-volume reference 
laboratories typically are quite competitive when it comes to cost. The use of informa-
tion technology is of increasing importance due to the rapid expansion of the use of 
integrated electronic health records. From a laboratory perspective, systems such as 
these function at their full potential only when used for test ordering, result reporting, 
and quality assessment. Moreover, because of their high cost, they are cost-effective 
when used for automated orders, reporting, and billing. In other words, manual test 
ordering and reporting are not congruent with the use of these systems. A significant 
part of the use of these systems is the ability to develop interfaces with reference 
laboratories so that test ordering and reporting are done via direct interfaces or 
through a middleware system.
It is apparent that many factors must be taken into consideration when selecting a 
reference laboratory (284) and that it is not an easy or straightforward decision, but 
consensus-based standards for assessing and selecting reference laboratories are now 
available (285).
PUBLIC HEALTH REQUIREMENTS
The laboratory community plays a critical role in the public health system and its 
efforts to control and eliminate TB in the United States. Each laboratory (hospital, 
commercial, reference, and public health), along with health care providers, plays 
integral roles in the treatment and management of TB patients and their contacts. The 
sooner a suspected TB case is reported to public health and TB control programs, the 
fewer transmissions and subsequent TB cases there will be. Public health reporting 
requirements vary widely from state to state. It is incumbent on the clinical laboratories 
to be aware of the TB reporting requirements (statutes, administrative code, and 
regulations) in their jurisdiction.
All 50 U.S. states and the District of Columbia have reporting requirements for TB 
disease. Eighty-five percent (44/52) of jurisdictions require reporting of positive AFB 
smears. Fifty-three percent (28/52) of jurisdictions require reporting of a positive TB 
culture within 24 h or within 1 business day of identification. The reported time frame 
for clinical reporting varies from immediately to up to 7 days or weekly. Twenty-three 
percent (12/52) of jurisdictions require reporting of phenotypic AST results. However, 
no jurisdiction currently requires reporting of molecular drug resistance results. Sixty-
TABLE 17 Laboratory information that may be reportable to public health programsa
Receipt of an order for a TB culture
Receipt of an order for a TB NAAT
Positive TB NAAT result
Positive AFB smear
Culture positive for suspected or confirmed Mycobacterium tuberculosis complex organism
Culture positive for NTM
Positive test for LTBI (positive TST or IGRA result)
Molecular and phenotypic AST results
aTB, tuberculosis; NAAT, nucleic acid amplification test; AFB, acid-fast bacilli; NTM, nontuberculous 
mycobacteria; LTBI, latent tuberculosis infection; TST, tuberculin skin test; IGRA, interferon gamma release 
assay; AST, antimicrobial susceptibility testing.
nine percent (36/52) of jurisdictions require submission of the TB isolate to a local or 
state public health laboratory for confirmation testing and submission to the national 
genotyping program. Electronic reporting is currently mandatory for 6 jurisdictions. 
Reporting of LTBI is required by 23% (12/52) of jurisdictions, some only for children 5 
years of age. Twenty-five percent (13/52) of jurisdictions require reporting of NTM (57).
Recently, researchers from the Oregon Health and Sciences University and the 
Oregon Health Authority described their experience with extrapulmonary NTM report-
ing. They also discussed possibilities of monitoring trends in pulmonary NTM disease 
either by mandatory reporting or by alternative methods, such as voluntary reporting 
of pulmonary isolates by laboratories supplemented by intermittent surveys and special 
surveillance projects (286).
Table 17 shows information/results that may require reporting to public health 
programs, which vary from state to state. If specimens are sent to a reference laboratory 
for testing, the referring laboratory is responsible for reporting the results to public 
health programs unless the reference laboratory has agreed to do the required report-
ing. For example, California mandates that if the referral laboratory is out of state, the 
California laboratory that receives the report is responsible for reporting the results to 
the public health system (287).
Additionally, there are various time requirements for reporting among public health 
departments. For example, in Wisconsin, the identification of a M. tuberculosis complex 
isolate from a culture or a positive M. tuberculosis complex NAAT result must be 
reported immediately to the public health program with a follow-up written report 
within 24 h (288); Nebraska requires reporting within 7 days of detection or diagnosis 
(289). Electronic laboratory reporting has been implemented in many jurisdictions and 
has increased the timeliness and efficiency of reporting to public health systems and 
decreased the burden on the laboratory.
Another important public health responsibility of the clinical laboratory is the 
submission of initial isolates from culture-confirmed TB patients to the public health 
laboratory for genotyping by the CDC Tuberculosis Genotyping Program (290). This 
program provides funding and support for universal genotyping with the goal of typing 
all M. tuberculosis complex culture-positive cases in the United States. The methods 
routinely used, as part of this program, include spoligotyping and mycobacterial 
interspersed repetitive unit (MIRU) analysis. If two TB patients have isolates with 
different genotypes, this indicates that the patients are not likely involved in the same 
chain of transmission. Genotyping, combined with epidemiological data, helps identify 
TB patients involved in recent transmissions, is a method for monitoring epidemiolog-
ical trends, and has significant impacts on TB control. Genotyping enables the earlier 
detection of outbreaks, resulting in more rapid responses and fewer transmissions. It 
may also identify TB cases with undetected epidemiological links and in unusual 
settings, including outbreaks that occur in patients residing in different jurisdictions. 
For the laboratory, genotyping identifies false-positive cultures that may be the result
of mislabeling of specimens, cross-contamination of cultures, or other problems (291). 
Ultimately, the timely submission of isolates to public health laboratories aids in the 
control of TB in the United States.
RESOURCE-LIMITED SETTINGS
TB surpassed HIV as the leading cause of death from infectious disease in the world 
in 2014 (15). Pulmonary TB is of great public concern, so not surprisingly, this is the sole 
or primary focus of mycobacterial diagnostics in resource-limited settings. Because 
many resource-limited settings continue to lack access to quality mycobacterial diag-
nostic testing, and because of continuing urgent public health concerns for controlling 
TB, expansion of access to and the capacity for mycobacterial testing should continue 
to emphasize TB.
The diagnosis and treatment of TB have a long history of being integrated with 
public health control programs. Thus, diagnostic testing should be aligned and 
appropriate for the capacity for patient evaluation and treatment in each location. 
AFB smears remain a mainstay of diagnosis because they provide rapid preliminary 
diagnostic information and a rough assessment of infectiousness and guide inter-
pretation of the results of rapid molecular diagnostic tests. In rural outpatient 
clinics, AFB smears may be the only practicable diagnostic test. As clinics become 
larger and have access to improved diagnostic testing, the introduction of rapid 
diagnostic tests such as line probe assays or the Xpert assay becomes feasible, 
although several factors come into play when deciding at which point these tests 
can be used in a cost-effective manner. In hospitals in larger cities, mycobacterial 
cultures become a practical approach, although many hospitals do not have the 
capacity to perform AST. Finally, teaching hospitals, large private hospitals, and 
national public health laboratories often have the capacity to provide the full scope 
of mycobacterial diagnostic testing.
The WHO has endorsed a number of diagnostic tests for TB control programs, 
including light-emitting diode (LED) microscopy (292), line probe assays (293, 294), 
and the Xpert assay (295), and more are under development. On a strict market 
basis, none of these tests would be affordable in most resource-limited areas, and 
thus, the WHO has developed partnerships with several governmental and non-
governmental organizations to reduce the acquisition cost to affordable levels. 
Unlike rapid diagnostic tests for malaria, for which there are dozens of products and 
manufacturers (296), only a few diagnostic tests for TB have been developed (297), 
thereby providing more standardized products, simpler supply chains, easier quality 
control programs, and better evaluation of the effectiveness of the products in TB 
control programs. In Spring 2016, the WHO updated its policy on drug-resistant TB 
treatment (298), allowing the use of a 7-drug regimen for only 9 to 12 months, 
instead of the 18- to 24-month regimen. To use this shorter MDR-TB regimen, drug 
resistance to second-line drugs needs to be excluded. In patients with confirmed 
RIF-resistant TB or MDR-TB, the Genotype MTBDRsl assay may be used as an initial 
direct test, over phenotypic culture-based AST, to detect resistance to FQ and to the 
second-line injectable drugs (299).
It is recognized that a detailed description of providing access to mycobacteri-
ology services in resource-limited countries is beyond the scope of this review. For 
such services to be effective, they must be integrated with systems for clinical care 
and public health programs, in part because they focus primarily on TB and not on 
other mycobacteria but also because the detection of drug resistance is of para-
mount concern. Rapid test turnaround times are also a critical issue because many 
patients in these settings are from rural areas and have only limited access to health 
care facilities (300).
CONCLUSION
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14. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. 2003. Tuberculosis.
Lancet 362:887–899. https://doi.org/10.1016/S0140-6736(03)14333-4.
15. World Health Organization. 2016. Global tuberculosis report 2016.
World Health Organization, Geneva, Switzerland.
16. Schmit KM, Wansaula Z, Pratt R, Price SF, Langer AJ. 2017. Tuberculo-
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Morb Mortal Wkly Rep 54:605–608.
18. California Department of Food and Agriculture. 2009. California update
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pdfs/tb/bovine_tb_update_021309.pdf. Accessed 21 September 2017.
19. Hlavsa MC, Moonan PK, Cowan LS, Navin TR, Kammerer JS, Morlock GP,
Crawford JT, Lobue PA. 2008. Human tuberculosis due to Mycobacte-
temporary traditional methods and the latest developments for the direct detection of 
AFB. They also stressed that if patient care and public health are always considered 
paramount, regardless of admission time or hospital type, etc., the concept of services 
at that time had several shortcomings. They proposed that one way to manage those 
challenges was to sort and allocate specimens per a system of priorities. A model Fast 
Track program for tuberculosis was created to form a network of laboratories to 
expedite testing for highly infectious TB suspects (302). With the establishment of such 
a network, when new assays are validated and implemented in the central laboratory, 
the entire network of enrolled submitting entities immediately benefits. Similar ap-
proaches were initiated in the United Kingdom (303) and in Portugal (304). There was 
a growing realization that no single method by itself is sufficient to address the entire 
spectrum of diagnostic challenges. To streamline the best choice for laboratory diag-
nosis and patient management, a centerpiece of this practice guideline is the ideal 
algorithm and alternative algorithms for testing specimens for mycobacterial diseases 
by utilizing this concept.
In the past 25 years, a tremendous change in the epidemiology of drug-resistant TB 
and pulmonary NTM has occurred, thus warranting even further shortening of turn-
around times. By the same token, molecular diagnostic assays are becoming the 
standard of care. With the plethora of tests available, ongoing communication between 
the health care provider and the laboratory is essential. In this review, we provide an 
in-depth discussion of the latest developments in mycobacteriology testing as well as 
a holistic approach to sample collection, reporting of laboratory results, and interpre-
tation of results for the health care provider.
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